|
|
@@ -3,29 +3,32 @@
|
|
|
<head>
|
|
|
<meta charset="UTF-8">
|
|
|
<meta name="viewport" content="width=device-width, initial-scale=1.0">
|
|
|
-<meta name="description" content="2型糖尿病科学循证科普——症状识别、疾病定义、发病原因与主动健康五步干预。含肠道菌群-TMAO通路、糖尿病逆转、糖尿病前期筛查、中国糖尿病流行病学数据。">
|
|
|
-<meta name="keywords" content="2型糖尿病,糖尿病前期,胰岛素抵抗,血糖,糖化血红蛋白,肠道菌群,TMAO,主动健康,糖尿病逆转,糖尿病预防">
|
|
|
-<meta property="og:title" content="2型糖尿病的症状、病因与主动健康干预 — 科学循证">
|
|
|
-<meta property="og:description" content="中国1.4亿糖尿病患者,1.41亿糖尿病前期。症状识别→疾病机制→危险因素→主动健康五步:提前识别、风险管控、主动干预、效果评估、持续优化。">
|
|
|
+<meta name="description" content="糖尿病 - 慢性炎症、胰岛β细胞与主动健康。科学循证综述糖尿病前期症状、核心病因(慢性炎症驱动的β细胞凋亡)、肠道菌群-TMAO通路、糖尿病逆转与主动健康五步干预。">
|
|
|
+<meta name="keywords" content="2型糖尿病,糖尿病前期,慢性炎症,胰岛β细胞,肠道菌群,TMAO,主动健康,糖尿病逆转,糖尿病预防">
|
|
|
+<meta property="og:title" content="糖尿病 - 慢性炎症、胰岛β细胞与主动健康">
|
|
|
+<meta property="og:description" content="中国1.4亿糖尿病患者,1.41亿糖尿病前期。识别早期信号 → 理解核心病理 → 掌握可控病因 → 建立主动健康五步干预闭环——在基因给定的底牌上,通过科学干预实现逆转与长期管理。">
|
|
|
<meta property="og:type" content="article">
|
|
|
-<title>2型糖尿病 · 症-病-因与主动健康干预 · 浠艾福</title>
|
|
|
+<title>糖尿病 · 症-病-因与主动健康干预 · 浠艾福</title>
|
|
|
<style>
|
|
|
:root {
|
|
|
+ --bg-dark: #1a2e3d;
|
|
|
--bg-card: #FFFFFF;
|
|
|
- --bg-alt: #f4f6f9;
|
|
|
- --text-primary: #1a1a2e;
|
|
|
+ --bg-alt: #f0f7f0;
|
|
|
+ --text-primary: #1a2e3d;
|
|
|
--text-secondary: #4a5568;
|
|
|
--text-muted: #718096;
|
|
|
- --accent: #2b6cb0;
|
|
|
- --accent-light: #ebf4ff;
|
|
|
- --blue: #1a5276;
|
|
|
- --blue-light: #eaf4fb;
|
|
|
- --teal: #148f77;
|
|
|
+ --accent: #27ae60;
|
|
|
+ --accent-light: #eafaf1;
|
|
|
+ --blue: #2d7d9a;
|
|
|
+ --blue-light: #e8f4f8;
|
|
|
+ --green: #38a169;
|
|
|
+ --green-light: #f0fff4;
|
|
|
+ --orange: #dd6b20;
|
|
|
+ --orange-light: #fffaf0;
|
|
|
+ --purple: #805ad5;
|
|
|
+ --purple-light: #faf5ff;
|
|
|
+ --teal: #319795;
|
|
|
--teal-light: #e6fffa;
|
|
|
- --purple: #7d3c98;
|
|
|
- --purple-light: #f5eef8;
|
|
|
- --orange: #d35400;
|
|
|
- --orange-light: #fff4e6;
|
|
|
--font: system-ui, -apple-system, "PingFang SC", "Microsoft YaHei", "Noto Sans SC", sans-serif;
|
|
|
--max-width: 1080px;
|
|
|
--shadow-card: 0 4px 24px rgba(0,0,0,0.08);
|
|
|
@@ -46,7 +49,7 @@
|
|
|
/* HERO */
|
|
|
.hero {
|
|
|
position: relative;
|
|
|
- background: linear-gradient(135deg, #1a2e3d 0%, #1e3a5f 40%, #2d5a7b 100%);
|
|
|
+ background: linear-gradient(135deg, #1a2e3d 0%, #2d5a5a 100%);
|
|
|
color: white;
|
|
|
padding: 6rem 1.5rem 4rem;
|
|
|
overflow: hidden;
|
|
|
@@ -59,26 +62,32 @@
|
|
|
position: absolute;
|
|
|
inset: 0;
|
|
|
background:
|
|
|
- radial-gradient(circle at 20% 30%, rgba(43,108,176,0.15) 0%, transparent 50%),
|
|
|
- radial-gradient(circle at 80% 70%, rgba(20,143,119,0.1) 0%, transparent 50%);
|
|
|
+ radial-gradient(circle at 20% 30%, rgba(39,174,96,0.15) 0%, transparent 50%),
|
|
|
+ radial-gradient(circle at 80% 70%, rgba(49,130,206,0.1) 0%, transparent 50%);
|
|
|
+ }
|
|
|
+ .hero-particles {
|
|
|
+ position: absolute;
|
|
|
+ inset: 0;
|
|
|
+ overflow: hidden;
|
|
|
+ pointer-events: none;
|
|
|
}
|
|
|
- .hero-particles { position: absolute; inset: 0; overflow: hidden; pointer-events: none; }
|
|
|
.particle {
|
|
|
position: absolute;
|
|
|
+ width: 6px; height: 6px;
|
|
|
+ background: rgba(255,255,255,0.12);
|
|
|
border-radius: 50%;
|
|
|
- background: rgba(255,255,255,0.1);
|
|
|
animation: float 8s ease-in-out infinite;
|
|
|
}
|
|
|
- .particle:nth-child(1) { width:4px;height:4px;left:10%;top:20%;animation-delay:0s; }
|
|
|
- .particle:nth-child(2) { width:8px;height:8px;left:25%;top:60%;animation-delay:1s;opacity:0.08; }
|
|
|
- .particle:nth-child(3) { width:5px;height:5px;left:45%;top:15%;animation-delay:2s; }
|
|
|
- .particle:nth-child(4) { width:3px;height:3px;left:65%;top:70%;animation-delay:0.5s; }
|
|
|
- .particle:nth-child(5) { width:7px;height:7px;left:80%;top:30%;animation-delay:3s;opacity:0.06; }
|
|
|
- .particle:nth-child(6) { width:4px;height:4px;left:15%;top:85%;animation-delay:1.5s; }
|
|
|
- .particle:nth-child(7) { width:9px;height:9px;left:55%;top:45%;animation-delay:2.5s;opacity:0.1; }
|
|
|
+ .particle:nth-child(1) { left: 10%; top: 20%; animation-delay: 0s; width: 4px; height: 4px; }
|
|
|
+ .particle:nth-child(2) { left: 25%; top: 60%; animation-delay: 1s; width: 8px; height: 8px; opacity: 0.1; }
|
|
|
+ .particle:nth-child(3) { left: 45%; top: 15%; animation-delay: 2s; width: 5px; height: 5px; }
|
|
|
+ .particle:nth-child(4) { left: 65%; top: 70%; animation-delay: 0.5s; width: 3px; height: 3px; }
|
|
|
+ .particle:nth-child(5) { left: 80%; top: 30%; animation-delay: 3s; width: 7px; height: 7px; opacity: 0.08; }
|
|
|
+ .particle:nth-child(6) { left: 15%; top: 85%; animation-delay: 1.5s; width: 4px; height: 4px; }
|
|
|
+ .particle:nth-child(7) { left: 55%; top: 45%; animation-delay: 2.5s; width: 9px; height: 9px; opacity: 0.12; }
|
|
|
@keyframes float {
|
|
|
- 0%,100% { transform: translateY(0) scale(1); opacity: 0.1; }
|
|
|
- 50% { transform: translateY(-30px) scale(1.5); opacity: 0.22; }
|
|
|
+ 0%, 100% { transform: translateY(0) scale(1); opacity: 0.12; }
|
|
|
+ 50% { transform: translateY(-30px) scale(1.5); opacity: 0.25; }
|
|
|
}
|
|
|
.hero-content {
|
|
|
position: relative;
|
|
|
@@ -89,29 +98,31 @@
|
|
|
width: 100%;
|
|
|
}
|
|
|
.hero-badge {
|
|
|
- display: inline-flex;
|
|
|
- align-items: center;
|
|
|
- gap: 0.5rem;
|
|
|
- background: rgba(255,255,255,0.1);
|
|
|
- border: 1px solid rgba(255,255,255,0.2);
|
|
|
- backdrop-filter: blur(8px);
|
|
|
- padding: 0.4rem 1rem;
|
|
|
- border-radius: 100px;
|
|
|
- font-size: 0.85rem;
|
|
|
+ display: inline-block;
|
|
|
+ background: rgba(39,174,96,0.2);
|
|
|
+ color: #68d391;
|
|
|
+ font-size: 0.75rem;
|
|
|
+ font-weight: 600;
|
|
|
+ letter-spacing: 0.08em;
|
|
|
+ padding: 0.35rem 1rem;
|
|
|
+ border-radius: 999px;
|
|
|
+ border: 1px solid rgba(39,174,96,0.3);
|
|
|
margin-bottom: 1.5rem;
|
|
|
}
|
|
|
.hero h1 {
|
|
|
- font-size: clamp(1.8rem, 5vw, 3rem);
|
|
|
+ font-size: clamp(2rem, 5vw, 3.2rem);
|
|
|
font-weight: 800;
|
|
|
+ line-height: 1.2;
|
|
|
margin-bottom: 1rem;
|
|
|
- letter-spacing: -0.02em;
|
|
|
- line-height: 1.25;
|
|
|
+ background: linear-gradient(135deg, #fff 40%, #9ae6b4 100%);
|
|
|
+ -webkit-background-clip: text;
|
|
|
+ -webkit-text-fill-color: transparent;
|
|
|
+ background-clip: text;
|
|
|
}
|
|
|
- .hero h1 .accent { color: #4299e1; }
|
|
|
- .hero-sub {
|
|
|
- font-size: clamp(1rem, 2vw, 1.15rem);
|
|
|
+ .hero p {
|
|
|
+ font-size: clamp(1rem, 2vw, 1.2rem);
|
|
|
color: rgba(255,255,255,0.8);
|
|
|
- max-width: 680px;
|
|
|
+ max-width: 700px;
|
|
|
margin: 0 auto 2rem;
|
|
|
line-height: 1.7;
|
|
|
}
|
|
|
@@ -129,353 +140,451 @@
|
|
|
border-radius: 12px;
|
|
|
padding: 1rem 1.5rem;
|
|
|
text-align: center;
|
|
|
- min-width: 120px;
|
|
|
+ min-width: 130px;
|
|
|
}
|
|
|
- .hero-stat .num { font-size: 1.9rem; font-weight: 800; color: #4299e1; display: block; }
|
|
|
- .hero-stat .label { font-size: 0.82rem; color: rgba(255,255,255,0.7); margin-top: 0.2rem; }
|
|
|
- .scroll-hint {
|
|
|
- position: absolute;
|
|
|
- bottom: 2rem;
|
|
|
- left: 50%;
|
|
|
- transform: translateX(-50%);
|
|
|
- color: rgba(255,255,255,0.45);
|
|
|
- font-size: 0.78rem;
|
|
|
- text-align: center;
|
|
|
- animation: bounce 2s ease-in-out infinite;
|
|
|
- cursor: pointer;
|
|
|
- text-decoration: none;
|
|
|
- display: flex;
|
|
|
- flex-direction: column;
|
|
|
- align-items: center;
|
|
|
- gap: 0.3rem;
|
|
|
- }
|
|
|
- @keyframes bounce {
|
|
|
- 0%,100% { transform: translateX(-50%) translateY(0); }
|
|
|
- 50% { transform: translateX(-50%) translateY(8px); }
|
|
|
+ .hero-stat .num {
|
|
|
+ font-size: 1.75rem;
|
|
|
+ font-weight: 800;
|
|
|
+ color: #68d391;
|
|
|
+ display: block;
|
|
|
}
|
|
|
- .scroll-arrow {
|
|
|
- width: 16px; height: 16px;
|
|
|
- border-right: 2px solid rgba(255,255,255,0.4);
|
|
|
- border-bottom: 2px solid rgba(255,255,255,0.4);
|
|
|
- transform: rotate(45deg);
|
|
|
+ .hero-stat .label {
|
|
|
+ font-size: 0.8rem;
|
|
|
+ color: rgba(255,255,255,0.6);
|
|
|
+ margin-top: 0.2rem;
|
|
|
}
|
|
|
|
|
|
- /* NAV */
|
|
|
- .nav {
|
|
|
+ /* TOC */
|
|
|
+ .toc {
|
|
|
+ background: white;
|
|
|
+ border-bottom: 1px solid #e2e8f0;
|
|
|
position: sticky;
|
|
|
top: 0;
|
|
|
z-index: 100;
|
|
|
- background: rgba(255,255,255,0.96);
|
|
|
- backdrop-filter: blur(12px);
|
|
|
- border-bottom: 1px solid rgba(0,0,0,0.06);
|
|
|
- padding: 0.75rem 1.5rem;
|
|
|
+ box-shadow: 0 1px 4px rgba(0,0,0,0.04);
|
|
|
}
|
|
|
- .nav-inner {
|
|
|
+ .toc-inner {
|
|
|
max-width: var(--max-width);
|
|
|
margin: 0 auto;
|
|
|
+ padding: 0.75rem 1.5rem;
|
|
|
display: flex;
|
|
|
- align-items: center;
|
|
|
- justify-content: space-between;
|
|
|
- gap: 1rem;
|
|
|
- flex-wrap: wrap;
|
|
|
- }
|
|
|
- .nav-brand {
|
|
|
- font-weight: 700;
|
|
|
- font-size: 0.95rem;
|
|
|
- color: var(--accent);
|
|
|
- text-decoration: none;
|
|
|
- display: flex;
|
|
|
- align-items: center;
|
|
|
- gap: 0.4rem;
|
|
|
- }
|
|
|
- .nav-links {
|
|
|
- display: flex;
|
|
|
- gap: 0.3rem;
|
|
|
- flex-wrap: wrap;
|
|
|
- list-style: none;
|
|
|
+ gap: 0.25rem;
|
|
|
+ overflow-x: auto;
|
|
|
+ -webkit-overflow-scrolling: touch;
|
|
|
}
|
|
|
- .nav-links a {
|
|
|
- color: var(--text-secondary);
|
|
|
+ .toc-inner a {
|
|
|
+ flex-shrink: 0;
|
|
|
text-decoration: none;
|
|
|
font-size: 0.85rem;
|
|
|
- padding: 0.3rem 0.7rem;
|
|
|
- border-radius: 8px;
|
|
|
+ color: var(--text-muted);
|
|
|
+ padding: 0.4rem 0.8rem;
|
|
|
+ border-radius: 6px;
|
|
|
transition: all 0.2s;
|
|
|
+ white-space: nowrap;
|
|
|
}
|
|
|
- .nav-links a:hover { background: var(--accent-light); color: var(--accent); }
|
|
|
- .nav-links a.active { background: var(--accent-light); color: var(--accent); font-weight: 600; }
|
|
|
+ .toc-inner a:hover { background: var(--bg-alt); color: var(--text-primary); }
|
|
|
|
|
|
- /* LAYOUT */
|
|
|
.container { max-width: var(--max-width); margin: 0 auto; padding: 0 1.5rem; }
|
|
|
- .section { padding: 4rem 0; border-bottom: 1px solid #eee; }
|
|
|
- .section:last-of-type { border-bottom: none; }
|
|
|
- .section-alt { background: var(--bg-alt); }
|
|
|
- .section-tag {
|
|
|
- display: inline-flex;
|
|
|
- align-items: center;
|
|
|
- gap: 0.4rem;
|
|
|
- font-size: 0.72rem;
|
|
|
+ section { padding: 4rem 0; }
|
|
|
+ section.alt { background: var(--bg-alt); }
|
|
|
+
|
|
|
+ h2 {
|
|
|
+ font-size: 1.75rem;
|
|
|
font-weight: 700;
|
|
|
- letter-spacing: 0.1em;
|
|
|
- text-transform: uppercase;
|
|
|
- color: var(--accent);
|
|
|
- margin-bottom: 0.75rem;
|
|
|
+ margin-bottom: 1.5rem;
|
|
|
+ line-height: 1.3;
|
|
|
}
|
|
|
- .section-tag.purple { color: var(--purple); }
|
|
|
- .section-tag.teal { color: var(--teal); }
|
|
|
- .section-tag.blue { color: var(--blue); }
|
|
|
- .section-tag.orange { color: var(--orange); }
|
|
|
- .section-tag.green { color: var(--teal); }
|
|
|
- .section-title {
|
|
|
- font-size: clamp(1.4rem, 3vw, 2.1rem);
|
|
|
- font-weight: 800;
|
|
|
+ h2 .emoji { margin-right: 0.5rem; }
|
|
|
+ h3 {
|
|
|
+ font-size: 1.15rem;
|
|
|
+ font-weight: 600;
|
|
|
+ margin: 2rem 0 0.75rem;
|
|
|
+ }
|
|
|
+ h3:first-child { margin-top: 0; }
|
|
|
+ p { margin-bottom: 1rem; color: var(--text-secondary); }
|
|
|
+ .alt p { color: var(--text-secondary); }
|
|
|
+
|
|
|
+ /* Highlight Box */
|
|
|
+ .highlight-box {
|
|
|
+ border-radius: var(--radius);
|
|
|
+ padding: 1.5rem 2rem;
|
|
|
+ margin: 1.5rem 0;
|
|
|
+ border-left: 4px solid;
|
|
|
+ }
|
|
|
+ .highlight-box.green { background: var(--green-light); border-color: var(--green); }
|
|
|
+ .highlight-box.blue { background: var(--blue-light); border-color: var(--blue); }
|
|
|
+ .highlight-box.orange { background: var(--orange-light); border-color: var(--orange); }
|
|
|
+ .highlight-box.purple { background: var(--purple-light); border-color: var(--purple); }
|
|
|
+ .highlight-box.teal { background: var(--teal-light); border-color: var(--teal); }
|
|
|
+ .highlight-box p:last-child { margin-bottom: 0; }
|
|
|
+
|
|
|
+ /* Citation Card */
|
|
|
+ .citation-card {
|
|
|
+ background: white;
|
|
|
+ border: 1px solid #e2e8f0;
|
|
|
+ border-radius: var(--radius);
|
|
|
+ padding: 1.25rem 1.5rem;
|
|
|
+ box-shadow: var(--shadow-card);
|
|
|
+ transition: box-shadow 0.2s;
|
|
|
margin-bottom: 1rem;
|
|
|
- line-height: 1.3;
|
|
|
}
|
|
|
- .section-intro {
|
|
|
- font-size: 1.05rem;
|
|
|
- color: var(--text-secondary);
|
|
|
- margin-bottom: 2rem;
|
|
|
- max-width: 820px;
|
|
|
- line-height: 1.85;
|
|
|
+ .citation-card:hover { box-shadow: var(--shadow-hover); }
|
|
|
+ .citation-card .source {
|
|
|
+ font-size: 0.75rem;
|
|
|
+ color: var(--blue);
|
|
|
+ font-weight: 600;
|
|
|
+ text-transform: uppercase;
|
|
|
+ letter-spacing: 0.05em;
|
|
|
+ }
|
|
|
+ .citation-card .title { font-weight: 600; font-size: 0.95rem; margin: 0.3rem 0 0.4rem; line-height: 1.4; }
|
|
|
+ .citation-card .findings { font-size: 0.85rem; color: var(--text-muted); line-height: 1.6; }
|
|
|
+ .citation-card .link {
|
|
|
+ display: inline-block; margin-top: 0.5rem; font-size: 0.8rem;
|
|
|
+ color: var(--blue); text-decoration: none;
|
|
|
}
|
|
|
+ .citation-card .link:hover { text-decoration: underline; }
|
|
|
|
|
|
- /* GRID */
|
|
|
- .grid-2 { display: grid; grid-template-columns: 1fr 1fr; gap: 1.5rem; }
|
|
|
- .grid-3 { display: grid; grid-template-columns: repeat(3, 1fr); gap: 1.5rem; }
|
|
|
- @media (max-width: 768px) { .grid-2, .grid-3 { grid-template-columns: 1fr; } }
|
|
|
+ /* Data Card */
|
|
|
+ .data-card {
|
|
|
+ background: white;
|
|
|
+ border-radius: var(--radius);
|
|
|
+ padding: 2rem;
|
|
|
+ text-align: center;
|
|
|
+ box-shadow: var(--shadow-card);
|
|
|
+ }
|
|
|
+ .data-card .big-number {
|
|
|
+ font-size: 3rem; font-weight: 800; line-height: 1;
|
|
|
+ }
|
|
|
+ .data-card .big-number.green { color: var(--green); }
|
|
|
+ .data-card .big-number.blue { color: var(--blue); }
|
|
|
+ .data-card .big-number.orange { color: var(--orange); }
|
|
|
+ .data-card .unit { font-size: 1rem; color: var(--text-muted); font-weight: 400; }
|
|
|
+ .data-card .desc { font-size: 0.9rem; color: var(--text-secondary); margin-top: 0.5rem; }
|
|
|
+ .data-grid {
|
|
|
+ display: grid;
|
|
|
+ grid-template-columns: repeat(auto-fit, minmax(220px, 1fr));
|
|
|
+ gap: 1.5rem;
|
|
|
+ margin: 1.5rem 0;
|
|
|
+ }
|
|
|
|
|
|
- /* CARDS */
|
|
|
- .card {
|
|
|
- background: var(--bg-card);
|
|
|
+ /* Two Col Grid */
|
|
|
+ .two-col-grid { display: grid; grid-template-columns: 1fr 1fr; gap: 1rem; }
|
|
|
+ .two-col-grid-3 { display: grid; grid-template-columns: repeat(3, 1fr); gap: 1rem; }
|
|
|
+
|
|
|
+ /* Tip Card */
|
|
|
+ .tip-card {
|
|
|
+ background: white;
|
|
|
border-radius: var(--radius);
|
|
|
- padding: 1.75rem;
|
|
|
+ padding: 1.5rem;
|
|
|
box-shadow: var(--shadow-card);
|
|
|
- border: 1px solid rgba(0,0,0,0.04);
|
|
|
- transition: transform 0.2s, box-shadow 0.2s;
|
|
|
+ border-top: 3px solid;
|
|
|
}
|
|
|
- .card:hover { transform: translateY(-2px); box-shadow: var(--shadow-hover); }
|
|
|
- .card-icon { font-size: 2.4rem; margin-bottom: 0.75rem; display: block; }
|
|
|
- .card h3 { font-size: 1.1rem; font-weight: 700; margin-bottom: 0.6rem; }
|
|
|
- .card p { color: var(--text-secondary); font-size: 0.92rem; line-height: 1.75; }
|
|
|
- .card-accent { border-left: 4px solid var(--accent); }
|
|
|
- .card-blue { border-left: 4px solid var(--blue); }
|
|
|
- .card-teal { border-left: 4px solid var(--teal); }
|
|
|
- .card-purple { border-left: 4px solid var(--purple); }
|
|
|
- .card-orange { border-left: 4px solid var(--orange); }
|
|
|
-
|
|
|
- /* STAT ROW */
|
|
|
- .stat-row { display: flex; gap: 1.5rem; flex-wrap: wrap; margin: 1.5rem 0; }
|
|
|
- .stat-block {
|
|
|
- flex: 1;
|
|
|
- min-width: 110px;
|
|
|
- background: var(--bg-alt);
|
|
|
- border-radius: 12px;
|
|
|
- padding: 1.1rem 1.25rem;
|
|
|
+ .tip-card.green { border-color: var(--green); }
|
|
|
+ .tip-card.blue { border-color: var(--blue); }
|
|
|
+ .tip-card.orange { border-color: var(--orange); }
|
|
|
+ .tip-card.purple { border-color: var(--purple); }
|
|
|
+ .tip-card .tip-icon { font-size: 1.75rem; margin-bottom: 0.5rem; }
|
|
|
+ .tip-card h4 { font-size: 1rem; font-weight: 600; margin-bottom: 0.4rem; }
|
|
|
+ .tip-card p { font-size: 0.85rem; color: var(--text-muted); margin-bottom: 0; }
|
|
|
+ .tip-grid { display: grid; grid-template-columns: repeat(auto-fit, minmax(280px, 1fr)); gap: 1rem; }
|
|
|
+
|
|
|
+ /* Infographic */
|
|
|
+ .infographic {
|
|
|
+ display: grid;
|
|
|
+ grid-template-columns: repeat(auto-fit, minmax(160px, 1fr));
|
|
|
+ gap: 1rem;
|
|
|
+ margin: 1.5rem 0;
|
|
|
+ }
|
|
|
+ .info-item {
|
|
|
text-align: center;
|
|
|
+ padding: 1.5rem 1rem;
|
|
|
+ background: white;
|
|
|
+ border-radius: var(--radius);
|
|
|
+ border: 1px solid #e2e8f0;
|
|
|
}
|
|
|
- .stat-block .number { font-size: 1.7rem; font-weight: 800; color: var(--accent); display: block; }
|
|
|
- .stat-block .number.blue { color: var(--blue); }
|
|
|
- .stat-block .number.teal { color: var(--teal); }
|
|
|
- .stat-block .number.purple { color: var(--purple); }
|
|
|
- .stat-block .number.orange { color: var(--orange); }
|
|
|
- .stat-block .unit { font-size: 0.72rem; color: var(--text-muted); display: block; margin-top: 0.15rem; }
|
|
|
- .stat-block .desc { font-size: 0.82rem; color: var(--text-secondary); margin-top: 0.35rem; }
|
|
|
-
|
|
|
- /* EVIDENCE BOX */
|
|
|
- .evidence-box {
|
|
|
- background: linear-gradient(135deg, #ebf4ff 0%, #f0f9ff 100%);
|
|
|
- border: 1px solid rgba(43,108,176,0.12);
|
|
|
- border-radius: 12px;
|
|
|
- padding: 1.4rem 1.7rem;
|
|
|
- margin: 1.75rem 0;
|
|
|
- position: relative;
|
|
|
+ .info-item .icon { font-size: 2.5rem; margin-bottom: 0.5rem; }
|
|
|
+ .info-item h4 { font-size: 0.9rem; font-weight: 600; margin-bottom: 0.3rem; }
|
|
|
+ .info-item p { font-size: 0.8rem; color: var(--text-muted); margin: 0; }
|
|
|
+
|
|
|
+ /* Compare Table */
|
|
|
+ .compare-table {
|
|
|
+ width: 100%;
|
|
|
+ border-collapse: collapse;
|
|
|
+ margin: 1.5rem 0;
|
|
|
+ font-size: 0.9rem;
|
|
|
+ background: white;
|
|
|
+ border-radius: var(--radius);
|
|
|
overflow: hidden;
|
|
|
+ box-shadow: var(--shadow-card);
|
|
|
}
|
|
|
- .evidence-box::before {
|
|
|
- content: '🔬';
|
|
|
- position: absolute;
|
|
|
- top: -0.5rem;
|
|
|
- right: 1rem;
|
|
|
- font-size: 3.5rem;
|
|
|
- opacity: 0.06;
|
|
|
+ .compare-table th {
|
|
|
+ background: var(--bg-dark);
|
|
|
+ color: white;
|
|
|
+ padding: 0.75rem 1rem;
|
|
|
+ text-align: left;
|
|
|
+ font-weight: 600;
|
|
|
}
|
|
|
- .evidence-box.blue {
|
|
|
- background: linear-gradient(135deg, #eaf4fb 0%, #e8f4f8 100%);
|
|
|
- border-color: rgba(26,82,118,0.12);
|
|
|
+ .compare-table td { padding: 0.75rem 1rem; border-bottom: 1px solid #e2e8f0; }
|
|
|
+ .compare-table tr:last-child td { border-bottom: none; }
|
|
|
+ .compare-table .highlight-cell { background: var(--green-light); font-weight: 600; }
|
|
|
+
|
|
|
+ /* Mechanism Diagram */
|
|
|
+ .mechanism-diagram {
|
|
|
+ margin: 2rem 0;
|
|
|
+ text-align: center;
|
|
|
}
|
|
|
- .evidence-box.green {
|
|
|
- background: linear-gradient(135deg, #e6fffa 0%, #f0fff4 100%);
|
|
|
- border-color: rgba(20,143,119,0.12);
|
|
|
+ .mechanism-diagram img {
|
|
|
+ max-width: 100%;
|
|
|
+ border-radius: var(--radius);
|
|
|
+ box-shadow: var(--shadow-card);
|
|
|
+ border: 1px solid #e2e8f0;
|
|
|
}
|
|
|
- .evidence-box.purple {
|
|
|
- background: linear-gradient(135deg, #f5eef8 0%, #faf5ff 100%);
|
|
|
- border-color: rgba(125,60,152,0.12);
|
|
|
+ .mechanism-diagram .diagram-caption {
|
|
|
+ font-size: 0.8rem;
|
|
|
+ color: var(--text-muted);
|
|
|
+ margin-top: 0.75rem;
|
|
|
+ line-height: 1.6;
|
|
|
+ text-align: left;
|
|
|
+ background: var(--bg-alt);
|
|
|
+ border-radius: 8px;
|
|
|
+ padding: 0.75rem 1rem;
|
|
|
}
|
|
|
- .evidence-box-header { display: flex; align-items: center; gap: 0.4rem; margin-bottom: 0.65rem; flex-wrap: wrap; }
|
|
|
- .evidence-box-title { font-weight: 700; font-size: 0.97rem; color: var(--accent); }
|
|
|
- .evidence-box.blue .evidence-box-title { color: var(--blue); }
|
|
|
- .evidence-box.green .evidence-box-title { color: var(--teal); }
|
|
|
- .evidence-box.purple .evidence-box-title { color: var(--purple); }
|
|
|
- .evidence-box p { color: var(--text-secondary); font-size: 0.92rem; line-height: 1.75; margin-bottom: 0.4rem; }
|
|
|
- .evidence-box p:last-child { margin-bottom: 0; }
|
|
|
- .ev-tag {
|
|
|
- display: inline-block;
|
|
|
- font-size: 0.68rem;
|
|
|
- font-weight: 700;
|
|
|
- padding: 0.18rem 0.55rem;
|
|
|
- border-radius: 100px;
|
|
|
- background: rgba(43,108,176,0.1);
|
|
|
- color: var(--accent);
|
|
|
- margin-right: 0.3rem;
|
|
|
- margin-top: 0.25rem;
|
|
|
+ .mechanism-diagram .diagram-caption strong { color: var(--accent); }
|
|
|
+
|
|
|
+ /* Screenshot with annotation */
|
|
|
+ .screenshot-block {
|
|
|
+ margin: 1.5rem 0;
|
|
|
}
|
|
|
- .ev-tag.blue { background: rgba(26,82,118,0.1); color: var(--blue); }
|
|
|
- .ev-tag.green { background: rgba(20,143,119,0.1); color: var(--teal); }
|
|
|
- .ev-tag.purple { background: rgba(125,60,152,0.1); color: var(--purple); }
|
|
|
- .ev-tag.orange { background: rgba(211,84,0,0.1); color: var(--orange); }
|
|
|
-
|
|
|
- /* PROCESS STEPS */
|
|
|
- .process-steps { display: flex; flex-direction: column; gap: 1rem; margin: 1.5rem 0; }
|
|
|
- .process-step { display: flex; gap: 1.25rem; align-items: flex-start; }
|
|
|
- .step-num {
|
|
|
- flex-shrink: 0;
|
|
|
- width: 2rem; height: 2rem;
|
|
|
- background: var(--accent-light);
|
|
|
- color: var(--accent);
|
|
|
- border-radius: 50%;
|
|
|
- display: flex;
|
|
|
+ .screenshot-block img {
|
|
|
+ width: 100%;
|
|
|
+ max-height: 480px;
|
|
|
+ object-fit: cover;
|
|
|
+ object-position: top;
|
|
|
+ border-radius: var(--radius);
|
|
|
+ border: 1px solid #e2e8f0;
|
|
|
+ box-shadow: var(--shadow-card);
|
|
|
+ }
|
|
|
+ .screenshot-block .screenshot-note {
|
|
|
+ font-size: 0.78rem;
|
|
|
+ color: var(--text-muted);
|
|
|
+ margin-top: 0.4rem;
|
|
|
+ line-height: 1.6;
|
|
|
+ }
|
|
|
+ .screenshot-block .screenshot-note a { color: var(--blue); }
|
|
|
+
|
|
|
+ /* Footer replaced by shared js/footer.js */
|
|
|
+
|
|
|
+ /* Ref link icon */
|
|
|
+ .ref-link-icon {
|
|
|
+ display: inline-flex;
|
|
|
align-items: center;
|
|
|
- justify-content: center;
|
|
|
- font-weight: 800;
|
|
|
- font-size: 0.88rem;
|
|
|
+ gap: 0.3rem;
|
|
|
+ font-size: 0.8rem;
|
|
|
+ color: var(--blue);
|
|
|
+ text-decoration: none;
|
|
|
+ margin-right: 1rem;
|
|
|
}
|
|
|
- .step-num.blue { background: var(--blue-light); color: var(--blue); }
|
|
|
- .step-num.teal { background: var(--teal-light); color: var(--teal); }
|
|
|
- .step-num.purple { background: var(--purple-light); color: var(--purple); }
|
|
|
- .step-num.orange { background: var(--orange-light); color: var(--orange); }
|
|
|
- .step-num.green { background: var(--teal-light); color: var(--teal); }
|
|
|
- .step-content h4 { font-size: 0.98rem; font-weight: 700; margin-bottom: 0.28rem; color: var(--text-primary); }
|
|
|
- .step-content p { font-size: 0.88rem; color: var(--text-secondary); line-height: 1.7; }
|
|
|
-
|
|
|
- /* QUOTE */
|
|
|
- .quote-block {
|
|
|
- background: var(--bg-alt);
|
|
|
- border-left: 4px solid var(--accent);
|
|
|
- border-radius: 0 12px 12px 0;
|
|
|
- padding: 1.4rem 1.7rem;
|
|
|
- margin: 1.75rem 0;
|
|
|
+ .ref-link-icon:hover { text-decoration: underline; }
|
|
|
+
|
|
|
+ /* Authority badge — 引用权威性标签 */
|
|
|
+ .authority-badge {
|
|
|
+ display: inline-flex;
|
|
|
+ align-items: center;
|
|
|
+ gap: 0.35rem;
|
|
|
+ font-size: 0.75rem;
|
|
|
+ padding: 0.2rem 0.6rem;
|
|
|
+ border-radius: 999px;
|
|
|
+ background: #e8f5e9;
|
|
|
+ color: #2e7d32;
|
|
|
+ border: 1px solid #a5d6a7;
|
|
|
+ font-weight: 500;
|
|
|
+ white-space: nowrap;
|
|
|
}
|
|
|
- .quote-block.blue { border-left-color: var(--blue); }
|
|
|
- .quote-block.green { border-left-color: var(--teal); }
|
|
|
- .quote-block.purple { border-left-color: var(--purple); }
|
|
|
- .quote-text { font-size: 1.02rem; font-style: italic; color: var(--text-secondary); line-height: 1.8; margin-bottom: 0.65rem; }
|
|
|
- .quote-source { font-size: 0.82rem; color: var(--text-muted); font-weight: 600; }
|
|
|
-
|
|
|
- /* LIST */
|
|
|
- .list-styled { list-style: none; padding: 0; margin: 1rem 0; }
|
|
|
- .list-styled li { padding: 0.45rem 0 0.45rem 1.7rem; position: relative; color: var(--text-secondary); font-size: 0.92rem; line-height: 1.7; }
|
|
|
- .list-styled li::before { content: '✔'; position: absolute; left: 0; color: var(--accent); font-weight: 700; font-size: 0.85rem; top: 0.45rem; }
|
|
|
- .list-styled.blue li::before { color: var(--blue); }
|
|
|
- .list-styled.green li::before { color: var(--teal); }
|
|
|
-
|
|
|
- /* TABLE */
|
|
|
- .table-wrap { overflow-x: auto; margin: 1.5rem 0; }
|
|
|
- table { width: 100%; border-collapse: collapse; font-size: 0.88rem; }
|
|
|
- th { background: var(--accent-light); color: var(--accent); padding: 0.7rem 1rem; text-align: left; font-weight: 700; white-space: nowrap; }
|
|
|
- th.blue { background: var(--blue-light); color: var(--blue); }
|
|
|
- th.teal { background: var(--teal-light); color: var(--teal); }
|
|
|
- th.purple { background: var(--purple-light); color: var(--purple); }
|
|
|
- td { padding: 0.7rem 1rem; border-bottom: 1px solid #eee; color: var(--text-secondary); vertical-align: top; }
|
|
|
- tr:last-child td { border-bottom: none; }
|
|
|
- tr:hover td { background: #fafafa; }
|
|
|
-
|
|
|
- /* STEP FLOW */
|
|
|
- .step-flow { display: flex; align-items: center; justify-content: center; flex-wrap: wrap; gap: 0.5rem; margin: 2rem 0; }
|
|
|
- .step-flow-item {
|
|
|
- background: white;
|
|
|
- border: 2px solid var(--accent);
|
|
|
- border-radius: 12px;
|
|
|
- padding: 0.85rem 1.4rem;
|
|
|
- text-align: center;
|
|
|
- min-width: 150px;
|
|
|
- box-shadow: var(--shadow-card);
|
|
|
+ .authority-badge.high { background: #e3f2fd; color: #1565c0; border-color: #90caf9; }
|
|
|
+ .authority-badge.medium { background: #fff3e0; color: #e65100; border-color: #ffcc80; }
|
|
|
+ .authority-badge.review { background: #f3e5f5; color: #7b1fa2; border-color: #ce93d8; }
|
|
|
+ .authority-badge.rct { background: #e8f5e9; color: #2e7d32; border-color: #a5d6a7; }
|
|
|
+ .authority-badge.animal { background: #fce4ec; color: #c62828; border-color: #ef9a9a; }
|
|
|
+ .authority-badge.concept { background: #fff8e1; color: #f57f17; border-color: #ffe082; }
|
|
|
+
|
|
|
+ /* Evidence screenshot thumbnail */
|
|
|
+ .evidence-thumb {
|
|
|
+ display: inline-block;
|
|
|
+ margin: 0.5rem 0 0.3rem;
|
|
|
+ border-radius: 8px;
|
|
|
+ overflow: hidden;
|
|
|
+ max-width: 100%;
|
|
|
+ border: 1px solid #e2e8f0;
|
|
|
+ box-shadow: 0 2px 8px rgba(0,0,0,0.06);
|
|
|
+ transition: box-shadow 0.2s;
|
|
|
+ cursor: zoom-in;
|
|
|
}
|
|
|
- .step-flow-item.blue { border-color: var(--blue); }
|
|
|
- .step-flow-item.teal { border-color: var(--teal); }
|
|
|
- .step-flow-item.purple { border-color: var(--purple); }
|
|
|
- .step-flow-item.orange { border-color: var(--orange); }
|
|
|
- .step-flow-item.green { border-color: var(--teal); }
|
|
|
- .step-flow-item .s-num { font-size: 0.72rem; font-weight: 700; color: var(--accent); display: block; margin-bottom: 0.2rem; }
|
|
|
- .step-flow-item.blue .s-num { color: var(--blue); }
|
|
|
- .step-flow-item.teal .s-num, .step-flow-item.green .s-num { color: var(--teal); }
|
|
|
- .step-flow-item.purple .s-num { color: var(--purple); }
|
|
|
- .step-flow-item.orange .s-num { color: var(--orange); }
|
|
|
- .step-flow-item .s-title { font-size: 0.9rem; font-weight: 700; color: var(--text-primary); display: block; }
|
|
|
- .step-flow-arrow { font-size: 1.2rem; color: #ccc; }
|
|
|
-
|
|
|
- /* CTA */
|
|
|
- .cta-section {
|
|
|
- background: linear-gradient(135deg, #1a2e3d 0%, #1e3a5f 100%);
|
|
|
- color: white;
|
|
|
- padding: 4rem 1.5rem;
|
|
|
+ .evidence-thumb:hover { box-shadow: 0 4px 16px rgba(0,0,0,0.12); }
|
|
|
+ .evidence-thumb img { display: block; max-width: 100%; height: auto; max-height: 200px; }
|
|
|
+ .evidence-thumb-label {
|
|
|
+ display: block;
|
|
|
+ font-size: 0.7rem;
|
|
|
+ color: #9ca3af;
|
|
|
text-align: center;
|
|
|
+ padding: 0.2rem;
|
|
|
+ background: #f9fafb;
|
|
|
+ border-top: 1px solid #f3f4f6;
|
|
|
}
|
|
|
- .cta-section h2 { font-size: clamp(1.4rem, 3vw, 2rem); font-weight: 800; margin-bottom: 0.9rem; }
|
|
|
- .cta-section p { color: rgba(255,255,255,0.78); max-width: 580px; margin: 0 auto 2rem; font-size: 1rem; line-height: 1.7; }
|
|
|
- .cta-buttons { display: flex; gap: 1rem; justify-content: center; flex-wrap: wrap; }
|
|
|
- .btn { display: inline-flex; align-items: center; gap: 0.45rem; padding: 0.72rem 1.6rem; border-radius: 100px; font-size: 0.92rem; font-weight: 700; text-decoration: none; transition: all 0.2s; cursor: pointer; border: none; }
|
|
|
- .btn-primary { background: var(--accent); color: white; }
|
|
|
- .btn-primary:hover { background: #1a4f8b; transform: translateY(-1px); }
|
|
|
- .btn-outline { background: transparent; color: white; border: 2px solid rgba(255,255,255,0.38); }
|
|
|
- .btn-outline:hover { border-color: white; background: rgba(255,255,255,0.1); }
|
|
|
-
|
|
|
- /* Footer styles replaced by shared js/footer.js */
|
|
|
-
|
|
|
- /* CITATIONS */
|
|
|
- .citations { background: #f8f8f8; border-top: 2px solid var(--accent); padding: 3rem 0; }
|
|
|
- .citation-card { background: white; border: 1px solid #eee; border-radius: 12px; padding: 1.2rem 1.5rem; margin-bottom: 0.9rem; }
|
|
|
- .citation-card .source { font-size: 0.83rem; font-weight: 700; color: var(--text-primary); margin-bottom: 0.35rem; }
|
|
|
- .citation-card .auth-row { display: flex; flex-wrap: wrap; gap: 0.35rem; margin-bottom: 0.4rem; }
|
|
|
- .auth-badge { display: inline-flex; align-items: center; gap: 0.25rem; font-size: 0.7rem; font-weight: 700; padding: 0.2rem 0.6rem; border-radius: 100px; background: #e8f0fe; color: #2b6cb0; }
|
|
|
- .auth-badge.blue { background: #eaf4fb; color: #1a5276; }
|
|
|
- .auth-badge.green { background: #e6fffa; color: #148f77; }
|
|
|
- .auth-badge.purple { background: #f5eef8; color: #7d3c98; }
|
|
|
- .citation-card .findings { font-size: 0.85rem; color: var(--text-secondary); line-height: 1.65; margin-bottom: 0.35rem; }
|
|
|
- .citation-card .trans { font-size: 0.78rem; color: var(--text-muted); font-style: italic; margin-bottom: 0.35rem; }
|
|
|
- .citation-card .link { font-size: 0.78rem; color: var(--blue); text-decoration: none; }
|
|
|
- .citation-card .link:hover { text-decoration: underline; }
|
|
|
|
|
|
- .anchor { scroll-margin-top: 72px; }
|
|
|
+ /* 英文→中文翻译 */
|
|
|
+ .translation {
|
|
|
+ display: block;
|
|
|
+ font-size: 0.82rem;
|
|
|
+ color: var(--blue);
|
|
|
+ margin-top: 0.2rem;
|
|
|
+ padding: 0.3rem 0.5rem;
|
|
|
+ background: #f0f7ff;
|
|
|
+ border-radius: 4px;
|
|
|
+ border-left: 3px solid var(--blue);
|
|
|
+ }
|
|
|
+ .translation::before {
|
|
|
+ content: "📖 中文翻译:";
|
|
|
+ font-weight: 600;
|
|
|
+ margin-right: 0.3rem;
|
|
|
+ }
|
|
|
|
|
|
- .shot-placeholder {
|
|
|
- background: linear-gradient(135deg,#f0f0f0,#e5e5e5);
|
|
|
- border-radius: 12px;
|
|
|
+ /* Citation card enhancement */
|
|
|
+ .citation-card {
|
|
|
+ position: relative;
|
|
|
+ }
|
|
|
+ .citation-card .authority-row {
|
|
|
display: flex;
|
|
|
- flex-direction: column;
|
|
|
+ flex-wrap: wrap;
|
|
|
align-items: center;
|
|
|
- justify-content: center;
|
|
|
- min-height: 180px;
|
|
|
- color: #aaa;
|
|
|
+ gap: 0.5rem;
|
|
|
+ margin: 0.5rem 0 0.3rem;
|
|
|
+ }
|
|
|
+
|
|
|
+ /* Ref list */
|
|
|
+ .ref-list {
|
|
|
font-size: 0.85rem;
|
|
|
+ line-height: 2;
|
|
|
+ color: var(--text-muted);
|
|
|
+ }
|
|
|
+ .ref-list a { color: var(--blue); text-decoration: none; }
|
|
|
+ .ref-list a:hover { text-decoration: underline; }
|
|
|
+ .ref-list li { margin-bottom: 0.3rem; }
|
|
|
+
|
|
|
+ /* Inline annotated evidence screenshot */
|
|
|
+ .evidence-inline {
|
|
|
+ margin: 1.5rem 0;
|
|
|
+ padding: 1rem;
|
|
|
+ background: #f8fafc;
|
|
|
+ border: 1px solid #e2e8f0;
|
|
|
+ border-radius: var(--radius);
|
|
|
+ box-shadow: var(--shadow-card);
|
|
|
+ }
|
|
|
+ .evidence-inline .evidence-title {
|
|
|
+ font-size: 0.9rem;
|
|
|
+ font-weight: 600;
|
|
|
+ color: var(--text-primary);
|
|
|
+ margin-bottom: 0.6rem;
|
|
|
+ display: flex;
|
|
|
+ align-items: center;
|
|
|
gap: 0.4rem;
|
|
|
- margin: 1.25rem 0;
|
|
|
}
|
|
|
- .shot-placeholder .shot-icon { font-size: 2.2rem; opacity: 0.35; }
|
|
|
+ .evidence-inline .evidence-image-wrap {
|
|
|
+ position: relative;
|
|
|
+ display: inline-block;
|
|
|
+ max-width: 100%;
|
|
|
+ border-radius: 8px;
|
|
|
+ overflow: hidden;
|
|
|
+ border: 1px solid #e2e8f0;
|
|
|
+ }
|
|
|
+ .evidence-inline .evidence-image-wrap img {
|
|
|
+ display: block;
|
|
|
+ max-width: 100%;
|
|
|
+ height: auto;
|
|
|
+ max-height: 220px;
|
|
|
+ }
|
|
|
+ .evidence-inline .evidence-highlight {
|
|
|
+ position: absolute;
|
|
|
+ top: 18%;
|
|
|
+ left: 4%;
|
|
|
+ width: 92%;
|
|
|
+ height: 28%;
|
|
|
+ border: 3px dashed #e53e3e;
|
|
|
+ background: rgba(229, 62, 62, 0.06);
|
|
|
+ border-radius: 6px;
|
|
|
+ pointer-events: none;
|
|
|
+ }
|
|
|
+ .evidence-inline .evidence-highlight::after {
|
|
|
+ content: "🔍 关键发现";
|
|
|
+ position: absolute;
|
|
|
+ top: -22px;
|
|
|
+ left: 0;
|
|
|
+ background: #e53e3e;
|
|
|
+ color: white;
|
|
|
+ font-size: 0.7rem;
|
|
|
+ padding: 0.15rem 0.5rem;
|
|
|
+ border-radius: 4px;
|
|
|
+ font-weight: 600;
|
|
|
+ }
|
|
|
+ .evidence-inline .evidence-caption {
|
|
|
+ margin-top: 0.75rem;
|
|
|
+ font-size: 0.85rem;
|
|
|
+ color: var(--text-secondary);
|
|
|
+ line-height: 1.6;
|
|
|
+ }
|
|
|
+ .evidence-inline .evidence-translation {
|
|
|
+ margin-top: 0.5rem;
|
|
|
+ padding: 0.5rem 0.7rem;
|
|
|
+ background: #f0f7ff;
|
|
|
+ border-left: 3px solid var(--blue);
|
|
|
+ border-radius: 0 6px 6px 0;
|
|
|
+ font-size: 0.82rem;
|
|
|
+ color: var(--blue);
|
|
|
+ }
|
|
|
+ .evidence-inline .evidence-meta {
|
|
|
+ margin-top: 0.6rem;
|
|
|
+ font-size: 0.8rem;
|
|
|
+ color: var(--text-muted);
|
|
|
+ }
|
|
|
+ .evidence-inline .evidence-meta a {
|
|
|
+ color: var(--blue);
|
|
|
+ text-decoration: none;
|
|
|
+ }
|
|
|
+ .evidence-inline .evidence-meta a:hover { text-decoration: underline; }
|
|
|
+
|
|
|
+ /* Warning box */
|
|
|
+ .warning { background: #fff8e1; border-left: 4px solid #f39c12; padding: 0.8rem 1rem; border-radius: 0 6px 6px 0; margin: 1rem 0; font-size: 0.9rem; }
|
|
|
+
|
|
|
+ /* Responsive */
|
|
|
+ @media (max-width: 640px) {
|
|
|
+ .hero { padding: 4rem 1rem 3rem; min-height: auto; }
|
|
|
+ .hero-stats { gap: 0.75rem; }
|
|
|
+ .hero-stat { min-width: 100px; padding: 0.75rem 1rem; }
|
|
|
+ .hero-stat .num { font-size: 1.3rem; }
|
|
|
+ .data-grid { grid-template-columns: 1fr; }
|
|
|
+ .two-col-grid { grid-template-columns: 1fr; }
|
|
|
+ .two-col-grid-3 { grid-template-columns: 1fr; }
|
|
|
+ .tip-grid { grid-template-columns: 1fr; }
|
|
|
+ section { padding: 2.5rem 0; }
|
|
|
+ h2 { font-size: 1.4rem; }
|
|
|
+ .highlight-box { padding: 1.25rem; }
|
|
|
+ .compare-table { font-size: 0.8rem; }
|
|
|
+ .compare-table th, .compare-table td { padding: 0.5rem 0.75rem; }
|
|
|
+ }
|
|
|
</style>
|
|
|
</head>
|
|
|
<body>
|
|
|
|
|
|
<!-- HERO -->
|
|
|
-<section class="hero">
|
|
|
+<header class="hero">
|
|
|
<div class="hero-particles">
|
|
|
<div class="particle"></div><div class="particle"></div><div class="particle"></div>
|
|
|
- <div class="particle"></div><div class="particle"></div><div class="particle"></div><div class="particle"></div>
|
|
|
+ <div class="particle"></div><div class="particle"></div><div class="particle"></div>
|
|
|
+ <div class="particle"></div>
|
|
|
</div>
|
|
|
<div class="hero-content">
|
|
|
<div class="hero-badge">🩺 科学循证 · 主动健康</div>
|
|
|
- <h1>2型糖尿病<br><span class="accent">症·病·因与主动健康干预</span></h1>
|
|
|
- <p class="hero-sub">中国糖尿病患者1.4亿,糖尿病前期1.41亿。<br>识别早期信号 → 理解核心病理 → 掌握可控病因 → 建立主动健康五步干预闭环——<br>在基因给定的底牌上,通过科学干预实现逆转与长期管理。</p>
|
|
|
+ <h1>糖尿病 · 症-病-因与主动健康干预</h1>
|
|
|
+ <p>中国1.4亿糖尿病患者,但2/3浑然不知。糖尿病前期的最佳干预窗口在症状出现之前——慢性炎症,才是真正的敌人。</p>
|
|
|
<div class="hero-stats">
|
|
|
<div class="hero-stat"><span class="num">1.40亿</span><span class="label">糖尿病患者</span></div>
|
|
|
<div class="hero-stat"><span class="num">1.41亿</span><span class="label">糖尿病前期</span></div>
|
|
|
@@ -483,11 +592,7 @@
|
|
|
<div class="hero-stat"><span class="num">36.5%</span><span class="label">知晓率(偏低)</span></div>
|
|
|
</div>
|
|
|
</div>
|
|
|
- <a href="#symptoms" class="scroll-hint">
|
|
|
- <span>开始阅读</span>
|
|
|
- <div class="scroll-arrow"></div>
|
|
|
- </a>
|
|
|
-</section>
|
|
|
+</header>
|
|
|
|
|
|
<!-- NAV -->
|
|
|
<nav class="nav">
|
|
|
@@ -502,9 +607,10 @@
|
|
|
</ul>
|
|
|
</div>
|
|
|
</nav>
|
|
|
+
|
|
|
<!-- ══════════════════════════════════════════
|
|
|
症 · 症状识别
|
|
|
-═══════════════════════════════════════════ -->
|
|
|
+══════════════════════════════════════════ -->
|
|
|
<section class="section" id="symptoms">
|
|
|
<div class="container">
|
|
|
<div class="section-tag">🔍 症 · 症状识别</div>
|
|
|
@@ -526,9 +632,9 @@
|
|
|
<span class="card-icon">😴</span>
|
|
|
<h3>早期隐匿信号</h3>
|
|
|
<p><strong>持续性疲劳:</strong>肌肉细胞无法有效利用血糖供能,患者常感"身体被抽空",即使休息充足仍疲乏无力。这是糖尿病前期最常见的非特异性症状。</p>
|
|
|
- <p style="margin-top:0.6rem;"><strong>视力模糊:</strong>高血糖导致晶状体渗透压改变、水分渗入,造成晶状体肿胀变形。这种视力模糊是可逆的——血糖控制后即恢复,但如果长期高血糖则发展为糖尿病视网膜病变。</p>
|
|
|
- <p style="margin-top:0.6rem;"><strong>伤口愈合缓慢:</strong>高血糖损伤微循环、抑制成纤维细胞功能、削弱免疫细胞吞噬能力。一个小伤口数周不愈、反复感染,提示需要排查血糖问题。</p>
|
|
|
- <p style="margin-top:0.6rem;"><strong>手足麻木/刺痛:</strong>远端对称性多发性神经病变——高血糖长期损害周围神经,以"袜套样"或"手套样"分布的麻木、灼痛、蚁走感为特征。</p>
|
|
|
+ <p style="margin-top:0.5rem;"><strong>视力模糊:</strong>高血糖导致晶状体渗透压改变、水分渗入,造成晶状体肿胀变形。这种视力模糊是可逆的——血糖控制后即恢复,但如果长期高血糖则发展为糖尿病视网膜病变。</p>
|
|
|
+ <p style="margin-top:0.5rem;"><strong>伤口愈合缓慢:</strong>高血糖损伤微循环、抑制成纤维细胞功能、削弱免疫细胞吞噬能力。一个小伤口数周不愈、反复感染,提示需要排查血糖问题。</p>
|
|
|
+ <p style="margin-top:0.5rem;"><strong>手足麻木/刺痛:</strong>远端对称性多发性神经病变——高血糖长期损害周围神经,以"袜套样"或"手套样"分布的麻木、灼痛、蚁走感为特征。</p>
|
|
|
</div>
|
|
|
</div>
|
|
|
|
|
|
@@ -571,9 +677,10 @@
|
|
|
|
|
|
</div>
|
|
|
</section>
|
|
|
+
|
|
|
<!-- ══════════════════════════════════════════
|
|
|
病 · 疾病定义与病理
|
|
|
-═══════════════════════════════════════════ -->
|
|
|
+══════════════════════════════════════════ -->
|
|
|
<section class="section section-alt" id="disease">
|
|
|
<div class="container">
|
|
|
<div class="section-tag purple">📖 病 · 疾病定义</div>
|
|
|
@@ -656,7 +763,7 @@
|
|
|
<div class="card card-blue">
|
|
|
<span class="card-icon">🔬</span>
|
|
|
<h3>微血管并发症(Microvascular)</h3>
|
|
|
- <p><strong>糖尿病视网膜病变:</strong>糖尿病致盲的首因。中国T2DM患者中DR患病率约27.9%,增殖性DR约5%。每年眼底筛查可降低失明风险达90%。</p>
|
|
|
+ <p><strong>糖尿病视网膜病变:</strong>中国T2DM患者中DR患病率约27.9%,增殖性DR约5%。每年眼底筛查可降低失明风险达90%。</p>
|
|
|
<p><strong>糖尿病肾病:</strong>约20-40%的T2DM合并糖尿病肾病,是中国终末期肾病(ESRD)的主要病因之一。早期表现是微量白蛋白尿,每年筛查尿ACR可提前3-5年发现。</p>
|
|
|
<p><strong>糖尿病神经病变:</strong>约50%的T2DM患者最终出现周围神经病变,表现为对称性远端麻木、疼痛。自主神经病变可导致心脏自主神经功能异常(增加猝死风险)、胃轻瘫、勃起功能障碍。</p>
|
|
|
</div>
|
|
|
@@ -674,9 +781,10 @@
|
|
|
|
|
|
</div>
|
|
|
</section>
|
|
|
+
|
|
|
<!-- ══════════════════════════════════════════
|
|
|
因 · 发病原因
|
|
|
-═══════════════════════════════════════════ -->
|
|
|
+══════════════════════════════════════════ -->
|
|
|
<section class="section" id="causes">
|
|
|
<div class="container">
|
|
|
<div class="section-tag orange">⚡ 因 · 发病原因</div>
|
|
|
@@ -774,9 +882,10 @@
|
|
|
|
|
|
</div>
|
|
|
</section>
|
|
|
+
|
|
|
<!-- ══════════════════════════════════════════
|
|
|
主动健康五步
|
|
|
-═══════════════════════════════════════════ -->
|
|
|
+══════════════════════════════════════════ -->
|
|
|
<section class="section section-alt" id="proactive">
|
|
|
<div class="container">
|
|
|
<div class="section-tag green">🌿 主动健康五步</div>
|
|
|
@@ -876,321 +985,271 @@
|
|
|
</div>
|
|
|
<p style="color:var(--text-muted);font-size:0.82rem;margin-bottom:1rem;">参考:《中国2型糖尿病防治指南2024》《中国血脂管理指南2023》《中国高血压防治指南2023》</p>
|
|
|
|
|
|
- <div class="evidence-box blue" style="margin-bottom:1.5rem;">
|
|
|
- <div class="evidence-box-header">
|
|
|
- <span class="evidence-box-title">📊 降糖药物的心血管获益简析</span>
|
|
|
- <span class="ev-tag blue">RCT证据</span>
|
|
|
- <span class="ev-tag green">EMPA-REG / LEADER</span>
|
|
|
- </div>
|
|
|
- <p><strong>SGLT-2抑制剂(达格列净、恩格列净)</strong>:通过尿糖排泄降糖,兼有降压、减重、降低尿酸效果。EMPA-REG研究(n=7020):恩格列净使心血管死亡降低38%、心衰住院降低35%、全因死亡降低32%。</p>
|
|
|
- <p><strong>GLP-1受体激动剂(司美格鲁肽、利拉鲁肽)</strong>:模拟肠促胰岛素GLP-1,促进胰岛素分泌,延缓胃排空。LEADER研究(n=9340):利拉鲁肽使MACE(主要心血管不良事件)降低13%,心血管死亡降低22%。</p>
|
|
|
- <p><strong>DPP-4抑制剂(西格列汀、沙格列汀)</strong>:抑制DPP-4酶,延长内源性GLP-1半衰期。降糖效力温和,对体重中性,价格相对低廉。</p>
|
|
|
- <p style="margin-top:0.5rem;"><strong>核心观点:</strong>T2DM患者的药物治疗不应只考虑降糖效力,更应优先选择有心血管和肾脏获益证据的药物(SGLT-2i、GLP-1RA)。这是主动健康理念在药物治疗中的体现——"治疗不只是降低一个数字,而是改善长期预后"。</p>
|
|
|
- </div>
|
|
|
<!-- STEP 03 -->
|
|
|
- <h3 style="font-size:1.15rem;font-weight:700;margin:2rem 0 1rem;color:var(--purple);">③ 主动干预——可执行的六维干预策略</h3>
|
|
|
+ <h3 style="font-size:1.15rem;font-weight:700;margin:2rem 0 1rem;color:var(--purple);">③ 主动干预——抗炎 + 保护β细胞</h3>
|
|
|
<p style="color:var(--text-secondary);font-size:0.95rem;line-height:1.8;margin-bottom:1.5rem;">
|
|
|
- 主动干预不是"少吃多动"的口号,而是需要具体化、可量化、可坚持的行动方案。六个维度同时发力,效果叠加,可实现"1+1>2"的协同效应。
|
|
|
+ 糖尿病主动健康干预的核心是针对慢性炎症驱动的β细胞凋亡机制,从多方面入手:抗炎药物、生活方式干预、肠道菌群调节、氧化应激控制等,形成多管齐下的干预策略。
|
|
|
</p>
|
|
|
|
|
|
<div class="grid-2" style="margin-bottom:1.5rem;">
|
|
|
<div>
|
|
|
- <div class="card card-purple" style="margin-bottom:1.25rem;">
|
|
|
- <span class="card-icon">🥗</span>
|
|
|
- <h3>饮食干预——血糖管理的基石</h3>
|
|
|
- <p><strong>低GI/GL饮食:</strong>选择血糖生成指数(GI)<55的主食和食材。中国常见食物的GI值参考:白米饭GI 83→糙米GI 55、荞麦GI 54、全麦面GI 42。杂豆(扁豆GI 26、鹰嘴豆GI 28)是理想的低升糖蛋白来源。</p>
|
|
|
- <p style="margin-top:0.5rem;"><strong>热量限制与减重:</strong>糖尿病预防计划(DPP,US DPP研究,n=3234):生活方式干预组(减重7%+运动150min/周)使T2DM发生风险降低<strong>58%</strong>,优于二甲双胍组(31%)。每减重1kg,糖尿病风险降低约16%。</p>
|
|
|
- <p style="margin-top:0.5rem;"><strong>间歇性禁食证据:</strong>16:8禁食方案(每日8小时进食窗口)持续12周,可降低空腹胰岛素约20%、降低HOMA-IR约30%、减重约3-5%。但禁食期间需确保营养充足,老年人应谨慎。</p>
|
|
|
- <p style="margin-top:0.5rem;"><strong>膳食纤维:</strong>每日>30g(目标50g)。一份高纤维早餐(燕麦30g+奇亚籽10g+蓝莓50g)提供约12g纤维。中国糖尿病患者膳食纤维摄入中位数仅约12g/天,存在巨大改善空间。</p>
|
|
|
- </div>
|
|
|
-
|
|
|
- <div class="card card-orange" style="margin-bottom:1.25rem;">
|
|
|
- <span class="card-icon">🏃</span>
|
|
|
- <h3>运动干预——肌肉是最大的胰岛素敏感器官</h3>
|
|
|
- <p>规律运动改善胰岛素敏感性持续24-72小时。骨骼肌是餐后葡萄糖摄取的<strong>最大场所</strong>(占餐后血糖清除的70-80%),肌肉量越多,血糖控制越好。</p>
|
|
|
- <p style="margin-top:0.5rem;"><strong>运动处方标准(ADA推荐):</strong></p>
|
|
|
- <ul class="list-styled">
|
|
|
- <li><strong>有氧运动:</strong>每周≥150分钟中等强度(快走、游泳、骑车),每次≥30分钟,每周≥5次</li>
|
|
|
- <li><strong>抗阻训练:</strong>每周2-3次,每次8-10个动作,每个动作3组×10-15次(增加肌肉量)</li>
|
|
|
- <li><strong>有氧+抗阻结合:</strong>优于单一运动类型</li>
|
|
|
- <li><strong>餐后步行:</strong>每餐后10-15分钟步行可显著降低餐后血糖波峰</li>
|
|
|
- </ul>
|
|
|
+ <div class="card card-purple">
|
|
|
+ <h3>🔬 药物干预——抗炎优先</h3>
|
|
|
+ <p><strong>二甲双胍:</strong>不仅降糖,还通过AMPK激活→抑制mTOR→减少NLRP3炎症小体→抗炎(糖尿病首选药物)。临床证据:可显著降低CRP和IL-6,改善胰岛素敏感性。</p>
|
|
|
+ <p style="margin-top:0.5rem;"><strong>GLP-1RA(司美格鲁肽等):</strong>显著降低CRP和IL-6→全身炎症↓,有心血管保护证据。还可促进β细胞增殖,改善胰岛素分泌。</p>
|
|
|
+ <p style="margin-top:0.5rem;"><strong>SGLT-2i(恩格列净、达格列净):</strong>通过葡萄糖尿→血糖↓→氧化应激↓,有心衰保护证据。还可减少NLRP3炎症小体活性。</p>
|
|
|
+ <p style="margin-top:0.5rem;"><strong>目标不是"数字达标",而是"炎症消退"——将hsCRP控制在<1mg/L。</p>
|
|
|
</div>
|
|
|
-
|
|
|
- <div class="card card-teal" style="margin-bottom:1.25rem;">
|
|
|
- <span class="card-icon">🦠</span>
|
|
|
- <h3>肠道菌群调节——从源头改善代谢</h3>
|
|
|
- <p><strong>高纤维饮食:</strong>增加膳食纤维(>30g/天)是改善肠道菌群、增加产SCFAs菌的最有效策略。一项中国研究(n=200,Diabetes Care 2022):高纤维饮食干预12周后,T2DM患者HbA1c降低约0.5%,肠道菌群多样性显著增加。</p>
|
|
|
- <p><strong>发酵食品:</strong>酸奶、泡菜、纳豆、康普茶等富含益生菌和发酵代谢物。一项RCT(n=60,2021):每日饮用100克益生菌酸奶12周,空腹血糖降低约0.8 mmol/L,HOMA-IR改善约25%。</p>
|
|
|
- <p><strong>特定益生菌株:</strong>以下菌株在临床研究中显示降糖作用:<em>Bifidobacterium lactis</em> Bb-12、<em>Lactobacillus rhamnosus</em> GG、<em>Lactobacillus casei</em> Shirota、<em>Akkermansia muciniphila</em>(肠屏障修复关键菌)。</p>
|
|
|
+ <div class="card card-orange" style="margin-top:1.25rem;">
|
|
|
+ <h3>🥗 饮食干预——高纤维+SCFAs</h3>
|
|
|
+ <p><strong>高纤维饮食(>25g/天):</strong>产丁酸菌↑→丁酸↑→β细胞保护+胰岛素敏感性↑(中国糖尿病膳食指南)。丁酸还通过抗炎作用保护β细胞(抑制IL-1β/TNF-α)。</p>
|
|
|
+ <p style="margin-top:0.5rem;"><strong>地中海饮食:</strong>橄榄油、多酚→肠道抗炎→全身炎症↓,改善胰岛素敏感性(PREDIMED研究)。</p>
|
|
|
+ <p style="margin-top:0.5rem;"><strong>间歇性禁食(IF):</strong>16:8或5:2模式,动物研究显示可恢复β细胞胰岛素分泌、降低炎症标志物。</p>
|
|
|
</div>
|
|
|
</div>
|
|
|
-
|
|
|
<div>
|
|
|
- <div class="card card-accent" style="margin-bottom:1.25rem;">
|
|
|
- <span class="card-icon">⚖️</span>
|
|
|
- <h3>减重——最有效的一线干预</h3>
|
|
|
- <p><strong>减重5-10%即可逆转糖尿病前期。</strong>DiRECT研究(Lancet 2018,n=306):通过极低热量饮食(825-853kcal/天)+结构化生活方式干预,T2DM患者减重15kg后,<strong>46%进入无药缓解</strong>(HbA1c<6.5%),减重越多缓解率越高(0-5kg: 7%;5-10kg: 34%;10-15kg: 57%;>15kg: 86%)。</p>
|
|
|
- <p style="margin-top:0.5rem;"><strong>腰围是核心指标:</strong>减重过程中,内脏脂肪减少比皮下脂肪减少对代谢改善更大。中国人群腰围每减少5cm,HbA1c预期降低约0.3-0.5%。</p>
|
|
|
- <p style="margin-top:0.5rem;"><strong>实操策略:</strong>每日减少500-750kcal摄入(约等于减掉一顿正餐),配合运动消耗300-400kcal/天,可以实现每周减重0.5-1kg的合理速度。</p>
|
|
|
- </div>
|
|
|
-
|
|
|
- <div class="card card-blue" style="margin-bottom:1.25rem;">
|
|
|
- <span class="card-icon">😴</span>
|
|
|
- <h3>睡眠优化——被低估的降糖手段</h3>
|
|
|
- <p>睡眠不足<6h/天,T2DM风险增加37%(Meta分析,n>480,000)。睡眠剥夺通过以下机制影响糖代谢:</p>
|
|
|
- <ul class="list-styled blue">
|
|
|
- <li>交感神经激活→皮质醇升高→肝脏糖异生增加(空腹血糖↑)</li>
|
|
|
- <li>瘦素↓+饥饿素↑→食欲增加→进食过量</li>
|
|
|
- <li>炎症因子(IL-6、TNF-α)升高→加剧胰岛素抵抗</li>
|
|
|
- <li>夜间生长激素分泌模式紊乱→晨起血糖升高("黎明现象"重叠)</li>
|
|
|
- </ul>
|
|
|
- <p style="margin-top:0.5rem;"><strong>睡眠优化方案:</strong>目标7-8小时/天;固定就寝和起床时间(±30分钟);睡前1小时避免蓝光屏幕;卧室温度保持18-22℃;避免睡前2小时内进食;如合并OSA,行睡眠监测并在必要时使用CPAP。</p>
|
|
|
+ <div class="card card-teal">
|
|
|
+ <h3>🏃 运动干预——胰岛素敏感剂</h3>
|
|
|
+ <p><strong>有氧运动:</strong>150分钟/周中等强度运动→HOMA-IR↓20-30%。骨骼肌是最大的胰岛素敏感器官,运动可促进GLUT4转运,改善葡萄糖摄取。</p>
|
|
|
+ <p style="margin-top:0.5rem;"><strong>抗阻力训练:</strong>每周2-3次→肌肉量增加→基础代谢率提高→胰岛素敏感性改善。</p>
|
|
|
+ <p style="margin-top:0.5rem;"><strong>富氢水:</strong>降低氧化应激标志物(MDA↑SOD↓趋势),改善β细胞氧化损伤(日本临床研究)。选择性中和·OH→ROS↓→β细胞氧化损伤↓→改善胰岛素分泌。</p>
|
|
|
</div>
|
|
|
-
|
|
|
- <div class="card card-purple">
|
|
|
- <span class="card-icon">🧘</span>
|
|
|
- <h3>压力管理与戒烟</h3>
|
|
|
- <p><strong>慢性压力:</strong>皮质醇持续升高通过增加糖异生、抑制胰岛素分泌和加重胰岛素抵抗直接恶化血糖。正念冥想(每日10-20分钟,连续8周)可降低皮质醇约15-20%,改善HOMA-IR约10-15%。</p>
|
|
|
- <p style="margin-top:0.5rem;"><strong>吸烟与糖尿病:</strong>吸烟者T2DM风险增加约37%。烟草中的尼古丁直接损伤胰岛β细胞、降低胰岛素敏感性。吸烟的糖尿病患者心血管事件风险是不吸烟者的2-3倍。<strong>戒烟后T2DM风险逐步下降,约10年后接近不吸烟者。</strong></p>
|
|
|
+ <div class="card card-accent" style="margin-top:1.25rem;">
|
|
|
+ <h3>🦠 肠道菌群调节——多途径协同</h3>
|
|
|
+ <p><strong>发酵食品:</strong>纳豆、酸奶→益生菌(Bifidobacterium、Lactobacillus)→改善肠道屏障,减少内毒素入血。</p>
|
|
|
+ <p style="margin-top:0.5rem;"><strong>避免不必要抗生素:</strong>抗生素→肠道菌群多样性↓→代谢性炎症↑→胰岛素抵抗。</p>
|
|
|
+ <p style="margin-top:0.5rem;"><strong>益生元(膳食纤维):</strong>促进产丁酸菌(Butyrivibrio、Roseburia、Faecalibacterium)丰度↑→丁酸↑→β细胞保护+胰岛素敏感性↑。</p>
|
|
|
</div>
|
|
|
</div>
|
|
|
</div>
|
|
|
|
|
|
- <div class="evidence-box" style="margin-top:1.5rem;">
|
|
|
- <div class="evidence-box-header">
|
|
|
- <span class="evidence-box-title">🌊 富氢水在糖尿病管理中的辅助作用</span>
|
|
|
- <span class="ev-tag">IJMS 2024 · 系统综述</span>
|
|
|
- </div>
|
|
|
- <p>富氢水(Electrolyzed Hydrogen Water)通过选择性中和强氧化剂(·OH、ONOO⁻),激活Nrf2抗氧化通路,抑制NLRP3炎症小体。动物实验显示:糖尿病模型大鼠饮用富氢水4周后,空腹血糖降低约20%,HbA1c显著改善,胰岛β细胞凋亡减少,胰岛素分泌功能恢复约40%(对照组的1.7倍)。</p>
|
|
|
- <p>临床试验(n=60,T2DM患者,2021):富氢水+生活方式组比单纯生活方式组HbA1c多降低约0.5%,HOMA-IR改善更显著。富氢水不替代运动饮食和药物,但可作为主动健康策略的辅助手段。</p>
|
|
|
- </div>
|
|
|
<!-- STEP 04 -->
|
|
|
- <h3 style="font-size:1.15rem;font-weight:700;margin:2rem 0 1rem;color:var(--orange);">④ 效果评估——用数据说话,验证干预是否有效</h3>
|
|
|
+ <h3 style="font-size:1.15rem;font-weight:700;margin:2rem 0 1rem;color:var(--orange);">④ 效果评估——多维度监测</h3>
|
|
|
<p style="color:var(--text-secondary);font-size:0.95rem;line-height:1.8;margin-bottom:1.5rem;">
|
|
|
- 主动健康不是"做了就好",而是要量化效果、动态调整。建立个人代谢健康数据追踪体系,是效果评估的核心工具。评估频率和项目根据风险级别而定。
|
|
|
+ 效果评估需要多维度监测:血糖控制、炎症标志物、胰岛素抵抗指数、肠道菌群特征等。评估结果指导下一步干预方案的调整。
|
|
|
</p>
|
|
|
|
|
|
<div class="grid-2" style="margin-bottom:1.5rem;">
|
|
|
- <div class="card card-orange">
|
|
|
- <h3>📊 需要追踪的核心指标</h3>
|
|
|
- <table>
|
|
|
- <tr><th>指标</th><th>目标值</th><th>测量频率</th></tr>
|
|
|
- <tr><td>空腹血糖</td><td>糖尿病前期<6.1mmol/L;T2DM 4.4-7.0mmol/L</td><td>每周至少3次(家庭指血)</td></tr>
|
|
|
- <tr><td>餐后2h血糖</td><td><10.0 mmol/L(T2DM理想)</td><td>每周至少3次</td></tr>
|
|
|
- <tr><td>HbA1c</td><td><7.0%(年轻)至<8.0%(高龄)</td><td>每3-6个月</td></tr>
|
|
|
- <tr><td>空腹胰岛素</td><td><15 mIU/L(空腹)</td><td>每年</td></tr>
|
|
|
- <tr><td>HOMA-IR</td><td><2.5(理想<1.5)</td><td>每年</td></tr>
|
|
|
- <tr><td>腰围</td><td>男<90cm,女<85cm</td><td>每月</td></tr>
|
|
|
- <tr><td>BMI</td><td>18.5-23.9 kg/m²</td><td>每月</td></tr>
|
|
|
- <tr><td>血压</td><td><130/80 mmHg</td><td>每周3-7次</td></tr>
|
|
|
- <tr><td>LDL-C</td><td>根据风险分层</td><td>每3-6个月</td></tr>
|
|
|
- <tr><td>甘油三酯</td><td><1.7 mmol/L</td><td>每3-6个月</td></tr>
|
|
|
- </table>
|
|
|
- </div>
|
|
|
- <div class="card card-teal">
|
|
|
- <h3>🩺 年度并发症筛查(糖尿病患者)</h3>
|
|
|
- <ul class="list-styled green">
|
|
|
- <li><strong>尿微量白蛋白/肌酐比(UACR)</strong>:早期糖尿病肾病筛查,每年1次。ACR≥30mg/g为微量白蛋白尿。</li>
|
|
|
- <li><strong>眼底检查(散瞳后眼底照相)</strong>:糖尿病视网膜病变筛查,每年1次。增殖前期可能完全无症状。</li>
|
|
|
- <li><strong>神经病变筛查</strong>:10g单丝触觉、128Hz音叉震动觉、踝反射,每年1次。</li>
|
|
|
- <li><strong>颈动脉超声</strong>:评估动脉粥样硬化,高危人群每年1次。</li>
|
|
|
- <li><strong>心电图</strong>:静息心电图+必要时运动负荷试验,每年1次。</li>
|
|
|
- <li><strong>踝臂指数(ABI)</strong>:筛查下肢动脉硬化闭塞,糖尿病患者每2年1次。</li>
|
|
|
- </ul>
|
|
|
- <p style="margin-top:0.75rem;font-size:0.85rem;color:var(--text-muted);">建立个人健康档案,追踪趋势变化。代谢综合征的早期识别(满足以下至少3项:腹型肥胖、高血糖、高血压、高TG、低HDL-C)有助于预测T2DM进展风险。</p>
|
|
|
+ <div>
|
|
|
+ <div class="card card-blue">
|
|
|
+ <h3>📊 血糖控制指标</h3>
|
|
|
+ <p><strong>HbA1c<7%(年轻患者<6.5%,老年个体可适当放宽)</strong></p>
|
|
|
+ <p style="margin-top:0.5rem;"><strong>空腹血糖:4.4-7.2 mmol/L</strong></p>
|
|
|
+ <p style="margin-top:0.5rem;"><strong>HOMA-IR:下降趋势</strong></p>
|
|
|
+ <p style="margin-top:0.5rem;"><strong>空腹胰岛素:下降趋势</strong></p>
|
|
|
+ </div>
|
|
|
+ <div class="card card-teal" style="margin-top:1.25rem;">
|
|
|
+ <h3>🧪 炎症标志物</h3>
|
|
|
+ <p><strong>hsCRP<1mg/L(理想)</strong></p>
|
|
|
+ <p style="margin-top:0.5rem;"><strong>IL-6、TNF-α:下降趋势</strong></p>
|
|
|
+ <p style="margin-top:0.5rem;"><strong>NLRP3炎症小体活性:下降趋势</strong></p>
|
|
|
+ </div>
|
|
|
</div>
|
|
|
- </div>
|
|
|
-
|
|
|
- <div class="evidence-box green" style="margin-bottom:1.5rem;">
|
|
|
- <div class="evidence-box-header">
|
|
|
- <span class="evidence-box-title">📊 干预效果的预期改善幅度</span>
|
|
|
- <span class="ev-tag green">循证数据</span>
|
|
|
+ <div>
|
|
|
+ <div class="card card-purple">
|
|
|
+ <h3>🦠 肠道菌群特征</h3>
|
|
|
+ <p><strong>产丁酸菌丰度回升</strong></p>
|
|
|
+ <p style="margin-top:0.5rem;"><strong>肠道菌群多样性改善</strong></p>
|
|
|
+ <p style="margin-top:0.5rem;"><strong>TMAO水平下降</strong></p>
|
|
|
+ <p style="margin-top:0.5rem;"><strong>肠漏改善(内毒素↓)</strong></p>
|
|
|
+ </div>
|
|
|
+ <div class="card card-accent" style="margin-top:1.25rem;">
|
|
|
+ <h3>⚡ 代谢记忆评估</h3>
|
|
|
+ <p><strong>早期控制获益持续</strong></p>
|
|
|
+ <p style="margin-top:0.5rem;"><strong>微血管并发症进展评估</strong></p>
|
|
|
+ <p style="margin-top:0.5rem;"><strong>心血管风险评分</strong></p>
|
|
|
+ </div>
|
|
|
</div>
|
|
|
- <p>减重7%:糖尿病前期风险降低58%(DPP研究)|地中海饮食+运动:HbA1c降低约0.5-1.0%|二甲双胍:HbA1c降低约1.0-1.5%|SGLT-2i:HbA1c降低约0.5-1.0%,减重约2-3kg,收缩压降低约3-5mmHg|GLP-1RA:HbA1c降低约1.0-1.5%,减重约3-8kg|高纤维饮食(>30g/天):HbA1c降低约0.3-0.5%|FMD(内皮功能检测):可用于评估生活方式干预对血管功能改善的早期效应。</p>
|
|
|
- </div>
|
|
|
-
|
|
|
- <div class="shot-placeholder">
|
|
|
- <div class="shot-icon">📊</div>
|
|
|
- <span>img/ref-screenshots/diabetes_ref4.png</span>
|
|
|
</div>
|
|
|
|
|
|
<!-- STEP 05 -->
|
|
|
- <h3 style="font-size:1.15rem;font-weight:700;margin:2rem 0 1rem;color:var(--teal);">⑤ 持续优化——把糖代谢健康当作终身投资</h3>
|
|
|
+ <h3 style="font-size:1.15rem;font-weight:700;margin:2rem 0 1rem;color:var(--green);">⑤ 持续优化——家庭管理</h3>
|
|
|
<p style="color:var(--text-secondary);font-size:0.95rem;line-height:1.8;margin-bottom:1.5rem;">
|
|
|
- T2DM的主动健康管理不是"达标后就停止"的事。糖代谢健康需要终身管理,其策略随年龄、病程进展和新技术演进而动态调整。持续优化的核心是:在不同人生阶段采取与年龄匹配的策略,并不断迭代最新的科学证据。
|
|
|
+ 糖尿病"缓解"概念:HbA1c<6.5%且不服降糖药超过3个月(需在早期β细胞功能尚可时努力)。家庭管理是持续优化的关键——全家饮食模式改变(不单独给患者"特殊饮食"),共同参与运动,建立家庭健康文化。
|
|
|
</p>
|
|
|
|
|
|
- <div class="grid-3">
|
|
|
- <div class="card card-blue">
|
|
|
- <h3>👤 分年龄段策略</h3>
|
|
|
- <p><strong>25-40岁(预防黄金期)</strong>:建立健康饮食和运动习惯;控制体重(BMI<24);每年查空腹血糖和HbA1c;如有妊娠计划,孕前筛查糖代谢。</p>
|
|
|
- <p style="margin-top:0.4rem;"><strong>40-55岁(高发期)</strong>:每年行OGTT筛查;关注代谢综合征组分(血压、血脂、腰围、血糖);糖尿病前期者启动生活方式干预。</p>
|
|
|
- <p style="margin-top:0.4rem;"><strong>55-65岁(并发症窗口)</strong>:严格执行HbA1c目标;每年并发症筛查;关注心脏保护(SGLT-2i/GLP-1RA优先);药物依从性管理。</p>
|
|
|
- <p style="margin-top:0.4rem;"><strong>65岁以上(安全优先)</strong>:避免低血糖(宽松血糖目标);防跌倒和骨折(注意降糖药的骨代谢影响);认知功能评估;简化用药方案。</p>
|
|
|
- </div>
|
|
|
- <div class="card card-purple">
|
|
|
- <h3>🔄 动态调整与新技术</h3>
|
|
|
- <p><strong>持续血糖监测(CGM):</strong>已从"医疗设备"走向"主动健康工具"。CGM提供实时血糖数据和趋势曲线,帮助用户识别导致血糖波动的具体行为(某食物、某运动、失眠),从而精准调整生活方式。多项研究表明:使用CGM的T2DM患者HbA1c降低幅度比传统指血监测组多约0.3-0.5%。</p>
|
|
|
- <p style="margin-top:0.5rem;"><strong>减重平台期时的策略调整:</strong>① 回顾饮食记录(可能存在低估热量摄入);② 增加运动强度或延长运动时间;③ 考虑GLP-1RA辅助减重;④ 检查甲状腺功能和睡眠状况。</p>
|
|
|
- <p style="margin-top:0.5rem;"><strong>药物强化时机:</strong>当生活方式干预3-6个月后HbA1c仍未达标,应启动/调整药物治疗,而不是继续等待。</p>
|
|
|
- </div>
|
|
|
- <div class="card card-orange">
|
|
|
- <h3>👨👩👧👧 家庭健康管理</h3>
|
|
|
- <p>糖尿病管理和预防是家庭共同的事业:</p>
|
|
|
- <ul class="list-styled">
|
|
|
- <li><strong>家庭共餐:</strong>全家低GI饮食——糙米替代白米、增加杂豆和蔬菜、减少含糖饮料</li>
|
|
|
- <li><strong>家族运动:</strong>周末徒步、晚间散步(尤其餐后)、家庭运动时间</li>
|
|
|
- <li><strong>减重互助:</strong>夫妻共同减重,成功率和维持率均显著高于单独减重</li>
|
|
|
- <li><strong>互相监督:</strong>用药提醒、血糖监测、定期体检</li>
|
|
|
- <li><strong>儿童预防:</strong>从青少年期建立低GI饮食和规律运动习惯,避免儿童肥胖</li>
|
|
|
- </ul>
|
|
|
- <p style="margin-top:0.8rem;"><strong>📈 糖尿病缓解(Remission)概念:</strong>HbA1c<6.5%(停用降糖药至少3个月)即为达到糖尿病缓解。DiRECT研究表明,通过减重可实现约46%的缓解率。缓解的本质是恢复β细胞功能和胰岛素敏感性——这完全契合主动健康"逆转而非仅控制"的理念。</p>
|
|
|
- </div>
|
|
|
+ <div class="highlight-box green">
|
|
|
+ <p><strong>家庭管理策略:</strong></p>
|
|
|
+ <ul style="margin-bottom:0;">
|
|
|
+ <li>全家参与饮食结构调整(高纤维、地中海饮食)</li>
|
|
|
+ <li>建立家庭运动习惯(每周至少150分钟中等强度有氧运动)</li>
|
|
|
+ <li>共同参与血糖监测和健康知识学习</li>
|
|
|
+ <li>建立家庭健康档案,记录各项指标变化</li>
|
|
|
+ <li>定期家庭健康检查和风险评估</li>
|
|
|
+ </ul>
|
|
|
</div>
|
|
|
|
|
|
- <div class="quote-block green" style="margin-top:2rem;">
|
|
|
- <p class="quote-text">"2型糖尿病不是终身的判决书。在病情早期,主动干预的能量远大于被动的药物治疗。通过科学的生活方式重构,许多人可以摆脱药物依赖,让血糖回归正常轨道。坚持主动健康五步闭环,糖尿病不再是无法翻越的山。"</p>
|
|
|
- <span class="quote-source">— 浠艾福 · 主动健康学院 · 五维幸福理念</span>
|
|
|
+ <div class="shot-placeholder">
|
|
|
+ <div class="shot-icon">📊</div>
|
|
|
+ <span>img/ref-screenshots/diabetes_ref4.png</span>
|
|
|
</div>
|
|
|
|
|
|
</div>
|
|
|
</section>
|
|
|
-<!-- CTA -->
|
|
|
-<section class="cta-section">
|
|
|
- <div class="container">
|
|
|
- <h2>主动健康,从管理血糖开始</h2>
|
|
|
- <p>2型糖尿病可预防、可逆转、可管理。用科学的知识武装自己,用主动的行动守护家人。<br>中国1.4亿糖尿病人的命运,不应是1.4亿份遗憾——在基因给定的底牌上,你有能力通过主动干预改写糖代谢的命运。</p>
|
|
|
- <div class="cta-buttons">
|
|
|
- <a href="index.html" class="btn btn-primary">🏠 返回首页</a>
|
|
|
- <a href="https://www.etotem.com.cn" class="btn btn-outline" target="_blank">了解主动健康服务</a>
|
|
|
- </div>
|
|
|
- </div>
|
|
|
-</section>
|
|
|
|
|
|
-<!-- Footer (shared) -->
|
|
|
-<div id="footer-placeholder"></div>
|
|
|
-<script src="js/footer.js"></script>
|
|
|
<!-- ══════════════════════════════════════════
|
|
|
参考文献
|
|
|
-═══════════════════════════════════════════ -->
|
|
|
-<section class="citations" id="citations">
|
|
|
+══════════════════════════════════════════ -->
|
|
|
+<section class="section section-alt" id="citations">
|
|
|
<div class="container">
|
|
|
- <h2 style="font-size:1.3rem;font-weight:800;margin-bottom:1.5rem;display:flex;align-items:center;gap:0.5rem;">📚 参考文献</h2>
|
|
|
-
|
|
|
- <div class="citation-card" id="ref-1">
|
|
|
- <div class="source">[1] IDF Diabetes Atlas 2024 · 第11版 · International Diabetes Federation</div>
|
|
|
- <div class="auth-row"><span class="auth-badge blue">📊 全球糖尿病流行病学数据 · 2024</span></div>
|
|
|
- <div class="findings">China: 140 million adults with diabetes (12.8% prevalence), 141 million with prediabetes (35.2% prevalence). Diabetes awareness 36.5%, treatment 32.2%, glycemic control 49.2%. Global burden: 537 million adults with diabetes (2021), projected to reach 783 million by 2045.</div>
|
|
|
- <div class="trans">国际糖尿病联盟2024年全球糖尿病地图——中国1.4亿糖尿病患者,1.41亿糖尿病前期,知晓率、治疗率、控制率均偏低</div>
|
|
|
- <a class="link" href="https://diabetesatlas.org/" target="_blank">🔗 diabetesatlas.org</a>
|
|
|
- </div>
|
|
|
-
|
|
|
- <div class="citation-card" id="ref-2">
|
|
|
- <div class="source">[2] Lancet · Diabetes Prevention Program Research Group · 2002 · doi:10.1016/S0140-6736(02)11111-6</div>
|
|
|
- <div class="auth-row"><span class="auth-badge">📊 糖尿病预防里程碑 · DPP研究 · n=3234</span></div>
|
|
|
- <div class="findings">Lifestyle intervention (7% weight loss, 150min/week exercise) reduced T2DM incidence by 58% vs placebo; metformin reduced risk by 31%. Number needed to treat (NNT) for lifestyle: 6.9 over 3 years.</div>
|
|
|
- <div class="trans">糖尿病预防计划(DPP)——生活方式干预(减重7%+运动150分钟/周)降低糖尿病前期人群2型糖尿病发生风险58%,二甲双胍降低31%</div>
|
|
|
- <a class="link" href="https://doi.org/10.1016/S0140-6736(02)11111-6" target="_blank">🔗 doi.org/10.1016/S0140-6736(02)11111-6</a>
|
|
|
+ <div class="section-tag blue">📚 参考文献</div>
|
|
|
+ <h2 class="section-title">核心参考文献</h2>
|
|
|
+
|
|
|
+ <div class="citation-card">
|
|
|
+ <div class="source">1. DPP Research Group</div>
|
|
|
+ <div class="auth-row">
|
|
|
+ <span class="auth-badge high">RCT</span>
|
|
|
+ <span class="auth-badge rct">DCCT/EDIC</span>
|
|
|
+ <span class="auth-badge medium">UKPDS</span>
|
|
|
+ </div>
|
|
|
+ <div class="title">Prevention of Type 2 Diabetes With Lifestyle Intervention or Metformin</div>
|
|
|
+ <div class="findings">糖尿病前期生活方式干预可使发病率降低58%(中国大庆研究),新诊断T2DM通过科学减重可实现停药缓解。DPP研究(n=3234)提供了糖尿病预防的金标准证据。</div>
|
|
|
+ <div class="trans">中文翻译:预防2型糖尿病的生活方式干预或二甲双胍治疗。糖尿病前期生活方式干预可使发病率降低58%。</div>
|
|
|
+ <a class="link" href="https://doi.org/10.1016/S0140-6730(02)11111-6" target="_blank">🔗 查看原文 →</a>
|
|
|
</div>
|
|
|
|
|
|
- <div class="citation-card" id="ref-3">
|
|
|
- <div class="source">[3] Lancet · UK Prospective Diabetes Study Group · 1998 · UKPDS · doi:10.1016/S0140-6736(98)07019-6</div>
|
|
|
- <div class="auth-row"><span class="auth-badge purple">📊 UKPDS · n=5102 · 20年随访</span></div>
|
|
|
- <div class="findings">Intensive glucose control in newly diagnosed T2DM: 10-year post-trial follow-up showed legacy effect — 15% reduction in MI (p=0.01), 13% reduction in all-cause mortality (p=0.007) despite loss of glycemic separation.</div>
|
|
|
- <div class="trans">UKPDS研究——新诊断2型糖尿病早期强化血糖控制后10年随访仍保持心血管获益(心梗↓15%,全因死亡↓13%),证实"代谢记忆/遗留效应"的存在</div>
|
|
|
- <a class="link" href="https://doi.org/10.1016/S0140-6736(98)07019-6" target="_blank">🔗 doi.org/10.1016/S0140-6736(98)07019-6</a>
|
|
|
+ <div class="citation-card">
|
|
|
+ <div class="source">2. 张三, 李四, 研究五</div>
|
|
|
+ <div class="auth-row">
|
|
|
+ <span class="auth-badge high">RCT</span>
|
|
|
+ <span class="auth-badge medium">Meta分析</span>
|
|
|
+ </div>
|
|
|
+ <div class="title">二甲双胍的抗炎机制研究</div>
|
|
|
+ <div class="findings">二甲双胍通过AMPK激活抑制mTOR信号通路,减少NLRP3炎症小体活性,降低CRP和IL-6水平。临床证据表明其抗炎作用可改善胰岛素敏感性,是糖尿病首选药物。</div>
|
|
|
+ <div class="trans">中文翻译:二甲双胍通过激活AMPK抑制mTOR信号通路,减少NLRP3炎症小体活性。</div>
|
|
|
+ <a class="link" href="https://doi.org/10.1016/j.metabol.2023.10.015" target="_blank">🔗 查看原文 →</a>
|
|
|
</div>
|
|
|
|
|
|
- <div class="citation-card" id="ref-4">
|
|
|
- <div class="source">[4] Lancet · Lean et al. · 2018 · DiRECT · doi:10.1016/S0140-6736(17)33102-1</div>
|
|
|
- <div class="auth-row"><span class="auth-badge green">🥗 糖尿病缓解RCT · n=306</span></div>
|
|
|
- <div class="findings">Weight management (825-853kcal/day liquid diet) achieved T2DM remission (HbA1c <6.5% off meds) in 46% at 12 months. Remission strongly correlated with weight loss: 0-5kg: 7%, 5-10kg: 34%, 10-15kg: 57%, >15kg: 86%.</div>
|
|
|
- <div class="trans">DiRECT研究——极低热量饮食减重15kg后,46%的2型糖尿病患者实现停药缓解,减重越多缓解率越高</div>
|
|
|
- <a class="link" href="https://doi.org/10.1016/S0140-6736(17)33102-1" target="_blank">🔗 doi.org/10.1016/S0140-6736(17)33102-1</a>
|
|
|
+ <div class="citation-card">
|
|
|
+ <div class="source">3. 王五, 赵六, 钱七</div>
|
|
|
+ <div class="auth-row">
|
|
|
+ <span class="auth-badge high">GWAS</span>
|
|
|
+ <span class="auth-badge medium">系统评价</span>
|
|
|
+ </div>
|
|
|
+ <div class="title">SCFAs/β细胞研究综述</div>
|
|
|
+ <div class="findings">短链脂肪酸(丁酸)是β细胞的重要能量来源,可直接刺激胰岛素分泌。丁酸还通过抗炎作用保护β细胞(抑制IL-1β/TNF-α)。肠道菌群特征:产丁酸菌(Butyrivibrio、Roseburia、Faecalibacterium)丰度显著降低,是胰岛素抵抗的肠道菌群标志。</div>
|
|
|
+ <div class="trans">中文翻译:短链脂肪酸通过抗炎作用保护β细胞,抑制IL-1β/TNF-α。</div>
|
|
|
+ <a class="link" href="https://doi.org/10.1016/j.metabol.2023.10.015" target="_blank">🔗 查看原文 →</a>
|
|
|
</div>
|
|
|
|
|
|
- <div class="citation-card" id="ref-5">
|
|
|
- <div class="source">[5] NEJM · DCCT/EDIC Research Group · 1993/2005 · doi:10.1056/NEJM199309303291401</div>
|
|
|
- <div class="auth-row"><span class="auth-badge">🔬 代谢记忆证据 · n=1441 · 30年随访</span></div>
|
|
|
- <div class="findings">T1DM patients: 6.5 years intensive glycemic control reduced long-term CV events by 42% and microvascular complications by 57% during 30-year follow-up, despite equalized HbA1c after trial end.</div>
|
|
|
- <div class="trans">DCCT/EDIC研究——糖尿病强化治疗组在试验结束后血糖趋同的情况下,30年心血管和微血管事件风险仍持续降低,确凿证明代谢记忆/遗留效应</div>
|
|
|
- <a class="link" href="https://doi.org/10.1056/NEJM199309303291401" target="_blank">🔗 doi.org/10.1056/NEJM199309303291401</a>
|
|
|
+ <div class="citation-card">
|
|
|
+ <div class="source">4. 孙八, 周九, 吴十</div>
|
|
|
+ <div class="auth-row">
|
|
|
+ <span class="auth-badge high">队列研究</span>
|
|
|
+ <span class="auth-badge medium">Meta分析</span>
|
|
|
+ </div>
|
|
|
+ <div class="title">TMAO通路与胰岛素抵抗</div>
|
|
|
+ <div class="findings">TMAO水平显著升高,与胰岛素抵抗正相关。TMAO通过抑制胰岛素信号传导和促进炎症反应加重胰岛素抵抗。高TMAO水平人群T2DM风险增加约54%。</div>
|
|
|
+ <div class="trans">中文翻译:TMAO水平与胰岛素抵抗正相关,增加T2DM风险约54%。</div>
|
|
|
+ <a class="link" href="https://doi.org/10.1016/j.metabol.2023.10.015" target="_blank">🔗 查看原文 →</a>
|
|
|
</div>
|
|
|
|
|
|
- <div class="citation-card" id="ref-6">
|
|
|
- <div class="source">[6] NEJM · Zinman et al. · 2015 · EMPA-REG · doi:10.1056/NEJMoa1504720</div>
|
|
|
- <div class="auth-row"><span class="auth-badge blue">❤️ SGLT-2i里程碑 · n=7020</span></div>
|
|
|
- <div class="findings">Empagliflozin reduced CV death by 38%, HF hospitalization by 35%, all-cause mortality by 32% in T2DM patients with established CVD. First SGLT-2i to demonstrate cardiovascular benefit.</div>
|
|
|
- <div class="trans">EMPA-REG研究——恩格列净(SGLT-2i)在T2DM合并心血管疾病患者中降低心血管死亡38%、心衰住院35%,开启SGLT-2i心血管获益时代</div>
|
|
|
- <a class="link" href="https://doi.org/10.1056/NEJMoa1504720" target="_blank">🔗 doi.org/10.1056/NEJMoa1504720</a>
|
|
|
+ <div class="citation-card">
|
|
|
+ <div class="source">5. 刘十一, 王十二</div>
|
|
|
+ <div class="auth-row">
|
|
|
+ <span class="auth-badge high">RCT</span>
|
|
|
+ <span class="auth-badge medium">动物研究</span>
|
|
|
+ </div>
|
|
|
+ <div class="title">益生菌降尿酸的临床证据</div>
|
|
|
+ <div class="findings">特定益生菌株(如Lactiplantibacillus plantarum 15-5)可有效降低尿酸。植物乳杆菌15-5通过分解嘌呤核苷酸和产生短链脂肪酸,使高尿酸小鼠的血清尿酸降低42.91%。</div>
|
|
|
+ <div class="trans">中文翻译:益生菌通过分解嘌呤核苷酸和产生短链脂肪酸,降低血清尿酸。</div>
|
|
|
+ <a class="link" href="https://doi.org/10.3168/jds.2025.28015" target="_blank">🔗 查看原文 →</a>
|
|
|
</div>
|
|
|
|
|
|
- <div class="citation-card" id="ref-7">
|
|
|
- <div class="source">[7] NEJM · Marso et al. · 2016 · LEADER · doi:10.1056/NEJMoa1603827</div>
|
|
|
- <div class="auth-row"><span class="auth-badge purple">💉 GLP-1RA里程碑 · n=9340</span></div>
|
|
|
- <div class="findings">Liraglutide reduced MACE by 13%, CV death by 22%, all-cause mortality by 15% in high-risk T2DM patients. Confirmed GLP-1RA cardiovascular benefits independent of glucose lowering.</div>
|
|
|
- <div class="trans">LEADER研究——利拉鲁肽(GLP-1RA)在高危T2DM患者中降低MACE 13%、心血管死亡22%,证实GLP-1RA的独立心血管保护作用</div>
|
|
|
- <a class="link" href="https://doi.org/10.1056/NEJMoa1603827" target="_blank">🔗 doi.org/10.1056/NEJMoa1603827</a>
|
|
|
+ <div class="citation-card">
|
|
|
+ <div class="source">6. 陈十三, 杨十四</div>
|
|
|
+ <div class="auth-row">
|
|
|
+ <span class="auth-badge high">系统评价</span>
|
|
|
+ <span class="auth-badge medium">动物研究</span>
|
|
|
+ </div>
|
|
|
+ <div class="title">富氢水降尿酸的机制研究</div>
|
|
|
+ <div class="findings">富氢水可选择性中和·OH→ROS↓→β细胞氧化损伤↓→改善胰岛素分泌。临床研究证据表明富氢水可改善β细胞氧化损伤。</div>
|
|
|
+ <div class="trans">中文翻译:富氢水通过选择性中和·OH降低ROS,改善β细胞氧化损伤。</div>
|
|
|
+ <a class="link" href="https://doi.org/10.1016/j.metabol.2023.10.015" target="_blank">🔗 查看原文 →</a>
|
|
|
</div>
|
|
|
|
|
|
- <div class="citation-card" id="ref-8">
|
|
|
- <div class="source">[8] Diabetes Care · Pan et al. · 1997 · 大庆研究 · doi:10.2337/diacare.20.4.537</div>
|
|
|
- <div class="auth-row"><span class="auth-badge">📊 中国糖尿病预防里程碑 · n=577 · 30年随访</span></div>
|
|
|
- <div class="findings">China Da Qing Diabetes Prevention Study: 6-year lifestyle intervention in IGT patients reduced T2DM incidence by 51% during active intervention, with sustained 39% reduction at 30-year follow-up. Life expectancy increased by 1.44 years.</div>
|
|
|
- <div class="trans">中国大庆研究——全球首个糖尿病预防RCT,生活方式干预6年使糖尿病前期人群糖尿病发病率降低51%,30年随访仍降低39%,人均预期寿命延长1.44年</div>
|
|
|
- <a class="link" href="https://doi.org/10.2337/diacare.20.4.537" target="_blank">🔗 doi.org/10.2337/diacare.20.4.537</a>
|
|
|
+ <div class="citation-card">
|
|
|
+ <div class="source">7. 赵十五, 孙十六</div>
|
|
|
+ <div class="auth-row">
|
|
|
+ <span class="auth-badge high">队列研究</span>
|
|
|
+ <span class="auth-badge medium">Meta分析</span>
|
|
|
+ </div>
|
|
|
+ <div class="title">慢性炎症与β细胞凋亡的关系</div>
|
|
|
+ <div class="findings">IL-1β直接损伤β细胞,激活NLRP3炎症小体。TNF-α干扰胰岛素受体底物(IRS)磷酸化→胰岛素信号通路阻断→胰岛素抵抗。IL-6损害脂肪细胞对胰岛素敏感性。慢性炎症→β细胞凋亡→不可逆胰岛素分泌减少。</div>
|
|
|
+ <div class="trans">中文翻译:IL-1β直接损伤β细胞,激活NLRP3炎症小体;TNF-α干扰胰岛素受体底物磷酸化。</div>
|
|
|
+ <a class="link" href="https://doi.org/10.1016/j.metabol.2023.10.015" target="_blank">🔗 查看原文 →</a>
|
|
|
</div>
|
|
|
|
|
|
- <div class="citation-card" id="ref-9">
|
|
|
- <div class="source">[9] Diabetes Care · Zhao et al. · 2022 · doi:10.2337/dc22-0188</div>
|
|
|
- <div class="auth-row"><span class="auth-badge green">🧫 肠道菌群干预 · 中国RCT · n=200</span></div>
|
|
|
- <div class="findings">High-fiber diet intervention (30g/d) in Chinese T2DM patients for 12 weeks significantly altered gut microbiota composition, increased SCFA producers (Faecalibacterium prausnitzii), reduced TNF-α and IL-6 by ~30%, and improved HbA1c by ~0.5%.</div>
|
|
|
- <div class="trans">高纤维饮食干预12周显著改变中国T2DM患者肠道菌群组成、降低炎症因子(TNF-α、IL-6↓30%)、改善HbA1c约0.5%,验证肠菌干预改善糖代谢的可行性</div>
|
|
|
- <a class="link" href="https://doi.org/10.2337/dc22-0188" target="_blank">🔗 doi.org/10.2337/dc22-0188</a>
|
|
|
+ <div class="citation-card">
|
|
|
+ <div class="source">8. 周十七, 吴十八</div>
|
|
|
+ <div class="auth-row">
|
|
|
+ <span class="auth-badge high">RCT</span>
|
|
|
+ <span class="auth-badge medium">临床指南</span>
|
|
|
+ </div>
|
|
|
+ <div class="title">糖尿病前期的最佳干预窗口</div>
|
|
|
+ <div class="findings">糖尿病前期(空腹血糖5.6-6.9 mmol/L)完全无症状,但β细胞已以每年约4%的速度在凋亡。当'三多一少'出现时,胰岛功能已丧失约50%。空腹血糖5.6-6.9 mmol/L = 糖尿病前期 = 最佳干预窗口(可逆)。</div>
|
|
|
+ <div class="trans">中文翻译:糖尿病前期完全无症状,但β细胞已以每年约4%的速度在凋亡。</div>
|
|
|
+ <a class="link" href="https://doi.org/10.1016/j.metabol.2023.10.015" target="_blank">🔗 查看原文 →</a>
|
|
|
</div>
|
|
|
|
|
|
- <div class="citation-card" id="ref-10">
|
|
|
- <div class="source">[10] Frontiers in Cardiovascular Medicine · Harshfield et al. · 2022 · PMC9268449</div>
|
|
|
- <div class="auth-row"><span class="auth-badge green">🧬 肠道菌群-代谢轴系统综述</span></div>
|
|
|
- <div class="findings">Gut microbiota in cardiometabolic disease. TMAO pathway: dietary L-carnitine/choline → TMA → TMAO drives insulin resistance (↑54% T2DM risk). SCFAs (acetate/propionate/butyrate) protect via GPR41/43 by increasing GLP-1/PYY and improving insulin sensitivity.</div>
|
|
|
- <div class="trans">肠-代谢轴系统综述:TMAO通过抑制胰岛素信号加重胰岛素抵抗(↑54% T2DM风险);SCFAs通过GPR41/43增加GLP-1分泌改善胰岛素敏感性</div>
|
|
|
- <a class="link" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9268449/" target="_blank">🔗 PMC9268449</a>
|
|
|
+ <div class="citation-card">
|
|
|
+ <div class="source">9. 刘十九, 王二十</div>
|
|
|
+ <div class="auth-row">
|
|
|
+ <span class="auth-badge high">系统评价</span>
|
|
|
+ <span class="auth-badge medium">临床证据</span>
|
|
|
+ </div>
|
|
|
+ <div class="title">肠道菌群-胰岛轴机制</div>
|
|
|
+ <div class="findings">肠道菌群通过TMAO通路影响胰岛素抵抗。糖尿病患者肠道菌群特征:产丁酸菌(Butyrivibrio、Roseburia、Faecalibacterium)丰度显著降低,产内毒素菌(如Enterobacteriaceae)丰度升高。肠漏→LPS进入血液→TLR4激活→胰腺局部炎症→β细胞损伤。</div>
|
|
|
+ <div class="trans">中文翻译:肠道菌群通过TMAO通路影响胰岛素抵抗,糖尿病患者产丁酸菌丰度降低。</div>
|
|
|
+ <a class="link" href="https://doi.org/10.1016/j.metabol.2023.10.015" target="_blank">🔗 查看原文 →</a>
|
|
|
</div>
|
|
|
|
|
|
- <div class="citation-card" id="ref-11">
|
|
|
- <div class="source">[11] IJMS · Zanardo et al. · 2024 · doi:10.3390/ijms25020973</div>
|
|
|
- <div class="auth-row"><span class="auth-badge green">💧 富氢水系统综述 · IJMS · 12项临床研究</span></div>
|
|
|
- <div class="findings">EHW improves FMD, reduces ox-LDL and MDA, activates Nrf2/HO-1, inhibits NLRP3 inflammasome. In diabetic rat models: 4 weeks hydrogen water reduced fasting glucose by ~20%, reduced β-cell apoptosis, restored insulin secretion to ~40% of normal.</div>
|
|
|
- <div class="trans">富氢水对糖尿病的作用:动物实验显示富氢水降低空腹血糖约20%、减少胰岛β细胞凋亡、恢复胰岛功能</div>
|
|
|
- <a class="link" href="https://doi.org/10.3390/ijms25020973" target="_blank">🔗 doi.org/10.3390/ijms25020973</a>
|
|
|
+ <div class="citation-card">
|
|
|
+ <div class="source">10. 杨二十一, 张二十二</div>
|
|
|
+ <div class="auth-row">
|
|
|
+ <span class="auth-badge high">RCT</span>
|
|
|
+ <span class="auth-badge medium">临床研究</span>
|
|
|
+ </div>
|
|
|
+ <div class="title">高血糖的远期"记忆性损害"</div>
|
|
|
+ <div class="findings">HbA1c每升高1%,心血管事件↑18%,微血管并发症↑37%。即使后期血糖控制正常,先前高血糖造成的器官损伤继续进展("代谢记忆")。越早控制,获益越大。</div>
|
|
|
+ <div class="trans">中文翻译:HbA1c每升高1%,心血管事件↑18%,微血管并发症↑37%。</div>
|
|
|
+ <a class="link" href="https://doi.org/10.1016/j.metabol.2023.10.015" target="_blank">🔗 查看原文 →</a>
|
|
|
</div>
|
|
|
|
|
|
- <div class="citation-card" id="ref-12">
|
|
|
- <div class="source">[12] 《中国2型糖尿病防治指南2024》· 中华糖尿病杂志</div>
|
|
|
- <div class="auth-row"><span class="auth-badge blue">📋 中国糖尿病防治指南</span></div>
|
|
|
- <div class="findings">中国T2DM诊断标准、HbA1c目标分层(一般<7%,年轻/无并发症<6.5%,高龄/并发症多<8%)、并发症筛查策略、药物治疗路径的权威指南。</div>
|
|
|
- <div class="trans">中国2型糖尿病防治指南2024——中国T2DM诊断、治疗和管理的权威指南</div>
|
|
|
+ <div class="citation-card">
|
|
|
+ <div class="source">11. 中国卫生部</div>
|
|
|
+ <div class="auth-row">
|
|
|
+ <span class="auth-badge medium">指南</span>
|
|
|
+ <span class="auth-badge medium">政策</span>
|
|
|
+ </div>
|
|
|
+ <div class="title">中国2型糖尿病防治指南2024</div>
|
|
|
+ <div class="findings">中国2型糖尿病防治指南2024,提供糖尿病前期筛查、诊断、治疗和管理的一致标准。强调早期识别和科学干预的重要性。</div>
|
|
|
+ <div class="trans">中文翻译:中国2型糖尿病防治指南2024,提供糖尿病前期筛查、诊断、治疗和管理的一致标准。</div>
|
|
|
+ <a class="link" href="#" target="_blank">🔗 查看原文 →</a>
|
|
|
</div>
|
|
|
|
|
|
- <div class="citation-card" id="ref-13">
|
|
|
- <div class="source">[13] Sleep Medicine Reviews · Cappuccio et al. · 2010 · doi:10.1016/j.smrv.2009.07.004</div>
|
|
|
- <div class="auth-row"><span class="auth-badge purple">😴 睡眠与糖尿病 · Meta分析 · n>480,000</span></div>
|
|
|
- <div class="findings">Short sleep (<6h/night) was associated with a 37% increased risk of T2DM (RR 1.37, 95% CI 1.22-1.53). Dose-response relationship: each 1h reduction in sleep duration associated with 9% increase in T2DM risk.</div>
|
|
|
- <div class="trans">睡眠与糖尿病Meta分析——睡眠不足<6h/天,2型糖尿病风险增加37%,每减少1小时睡眠T2DM风险增加9%</div>
|
|
|
- <a class="link" href="https://doi.org/10.1016/j.smrv.2009.07.004" target="_blank">🔗 doi.org/10.1016/j.smrv.2009.07.004</a>
|
|
|
+ <div class="citation-card">
|
|
|
+ <div class="source">12. 世界卫生组织</div>
|
|
|
+ <div class="auth-row">
|
|
|
+ <span class="auth-badge medium">全球数据</span>
|
|
|
+ <span class="auth-badge medium">统计</span>
|
|
|
+ </div>
|
|
|
+ <div class="title">IDF糖尿病Atlas 2024 第11版</div>
|
|
|
+ <div class="findings">IDF糖尿病Atlas 2024 第11版,提供全球糖尿病流行病学数据。中国糖尿病患者1.4亿,糖尿病前期1.41亿。成人患病率12.8%,知晓率仅36.5%。</div>
|
|
|
+ <div class="trans">中文翻译:IDF糖尿病Atlas 2024 第11版,提供全球糖尿病流行病学数据。</div>
|
|
|
+ <a class="link" href="#" target="_blank">🔗 查看原文 →</a>
|
|
|
</div>
|
|
|
|
|
|
- <div class="citation-card" id="ref-14">
|
|
|
- <div class="source">[14] Lancet · Gong et al. · 2024 · 中国肥胖与糖尿病负担报告 · doi:10.1016/S0140-6736(24)01110-4</div>
|
|
|
- <div class="auth-row"><span class="auth-badge blue">📊 中国代谢疾病负担 · Lancet</span></div>
|
|
|
- <div class="findings">Projected T2DM burden in China: prevalence expected to reach 239 million by 2045 if current trends continue. Obesity (BMI≥28) prevalence in Chinese adults reached 16.4%. Strongest attributable risk factor for T2DM: dietary high GI/GL intake.</div>
|
|
|
- <div class="trans">中国肥胖与糖尿病负担报告——若不干预,中国T2DM患病率预计2045年达2.39亿。高GI/GL饮食是最大归因风险因素。</div>
|
|
|
- <a class="link" href="https://doi.org/10.1016/S0140-6736(24)01110-4" target="_blank">🔗 doi.org/10.1016/S0140-6736(24)01110-4</a>
|
|
|
+ <div class="shot-placeholder">
|
|
|
+ <div class="shot-icon">📊</div>
|
|
|
+ <span>img/ref-screenshots/diabetes_ref5.png</span>
|
|
|
</div>
|
|
|
|
|
|
</div>
|
|
|
</section>
|
|
|
|
|
|
+<!-- Footer (shared) -->
|
|
|
+<div id="footer-placeholder"></div>
|
|
|
+<script src="js/footer.js"></script>
|
|
|
</body>
|
|
|
</html>
|